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ABSTRACT 
 Recently it was shown that circulating murine Ly6C+ monocytes can traffic from the 
blood to tissues and/or draining lymph nodes (LNs) after ingesting soluble antigens, and 
then cross-present antigenic fragments to induce CD8+ T cell proliferation. This importantly 
occurs with minimal alteration in monocyte molecular phenotype, suggesting that monocytes 
are not required to differentiate into macrophages or dendritic cells (DCs). However, these 
studies focused on soluble antigens, and few studies have addressed monocyte uptake and 
cross-presentation of cell-associated antigens within or upon apoptotic cells.  
Therefore, I raised the question of whether or not splenic Ly6C+ monocytes can 
engulf dying cells (efferocytose), and if so, can they can present antigens derived from the 
apoptotic cells onto MHC Class I molecules for the induction of CD8+ T cell activation and 
proliferation. First, I demonstrated that unstimulated monocytes can efferocytose and 
present peptide fragments from apoptotic cells and induce CD8+ T cell proliferation. 
Additionally, I stimulated relevant Toll-like receptors (TLRs) on monocytes with synthetic 
ligands and found that TLR ligation and signaling efferocytosis both in vitro and in vivo. 
Additionally, in vitro, specifically R848 (TRL7/8L)-activated Ly6C+ monocytes enhanced 
CD8+ T cell proliferation; however, downstream T cell proliferation was independent of TLR 
signaling. As such, R848 responses tested in vivo did not promote the proliferation or 
differentiation of CD8+ T cells into their cytotoxic function, or cross-prime. 
These studies highlight two findings. First, Ly6C+ monocytes can efferocytose and 
present apoptotic cell-derived antigens. Second, I illustrate a dichotomy of TLR signaling 
among cellular processes, in which TLR signaling in Ly6C+ monocytes primarily enhance 
antigen acquisition but as of yet, does not clearly enhance cross-presentation. Collectively, 
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this data corroborates with the emerging concept that monocytes are effector cells that can 
contribute to both innate and adaptive immunity. As correlative monocyte populations have 
been identified in humans, addressing these questions are imperative, with high prospect 
translating mouse models to humans. 
 
The form and content of this abstract are approved. I recommend its publication. 
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INTRODUCTION: LY6C+ MONOCYTE ACQUISITION AND CROSS-PRESENTATION OF 
CELL-ASSOCIATED ANTIGEN 
Introduction 
 The removal of dying cells is a crucial homeostatic process and is also important for 
the regulation of organismal immunity. Upon sterile (i.e., burn, irradiation cancer) or 
pathogenic assault (i.e., bacterial, fungal, viral infection), dying cells must be cleared to 
prevent further tissue damage and potentially autoimmunity1. Innate myeloid phagocytes 
(neutrophils, monocytes, macrophages and dendritic cells) play critical roles in scavenging, 
processing and in some scenarios presenting antigenic material from the apoptotic cells to 
induce CD8+ T cell adaptive immune responses.  
Of the mononuclear phagocytes, monocytes were initially described as a precursor 
cell to inflammatory macrophages or dendritic cells. However, emerging evidence has 
shown that they play integral roles in shaping cellular adaptive immunity. Yet, the ability of 
monocytes, particularly Ly6C+ monocytes that can reside in tissues, to engulf apoptotic cell 
derived antigens to initiate CD8+ T cell responses has not been extensively studied.  
The objective of this thesis is to determine if splenic ‘tissue-resident’ Ly6C+ 
monocytes can acquire, cross-present and cross-prime apoptotic cell-associated antigens. 
First, I will introduce Ly6C+ monocytes, the acquisition of apoptotic cells and antigen 
presentation (Chapter I). Then, I will discuss the ability of unstimulated Ly6C+ monocytes to 
acquire cell-associated antigens and load peptides onto MHC Class I molecules to present 
to CD8+ T cells (Chapter III). Following, I will discuss how Toll-like receptor (TLR)-activated 
Ly6C+ monocytes can perform these functions, in addition to cross-priming cytotoxic T cell 
responses (Chapter IV). Lastly, I will discuss the implications of monocyte contribution to 




An Introduction to Ly6C+ Monocytes 
Historical perspective - monocytes as professional phagocytes 
 The mononuclear phagocytic system (MPS) is currently comprised of three 
fundamental cell types – macrophages, monocytes and dendritic cells2,3. As the name 
suggests, these cells are characterized morphologically and functionally by a single-lobed 
nucleus and the ability to engulf cellular and foreign material, respectively. Despite this 
simplistic description, over a century of work has proven the complexity of these similar, yet 
quite different, cell types. 
The first description of the phagocyte regarding host defense was by Elie Metchnikoff 
in the late 1800’s, who coined the term “eating to defend” upon observation of amoeboid-like 
cells (macrophages) engulfing foreign material4. In addition to the well-characterized 
macrophage, the observation of circulating monocytes and their ability to phagocytose was 
described as early as 1930. In fact, they were considered more phagocytic than 
macrophages when comparing particles acquired in proportion to cytoplasm size5. Of 
important note, Clark and Clark described that during non-inflammatory conditions 
monocytes extravasated from the blood to reside in tissues without acquiring typical 
macrophage characteristics (increased size and reduced motility). Additionally, during 
inflammation recruited monocytes that remained undifferentiated (non-macrophage-like) 
could no longer be found at the site of insult just after a day5. While the authors were making 
the promonocyte-to-macrophage transition argument, extending their observations leads to 
an alternative view of the role of monocytes in host defense. Their compiled data suggests 
that a population of monocytes can reside in tissues without further differentiation, and 
furthermore, have the unique ability to re-enter circulation. Later, in the early 1970’s, 
Steinman and Cohn published a series introducing a third novel mononuclear tissue-




Murine monocyte development  
Monopoiesis is first observed in the fetal liver, beginning E12, continuing within the 
bone marrow E15 throughout adulthood11. Pluripotent hematopoietic stem cells (HSC) give 
rise to the common myeloid precursor (CMP), then to the granulocyte/macrophage 
precursor (GMP)12–14.  Beginning with the HSC, the transcription factor PU.1 is essential for 
downstream monocyte development14,15. High expression of PU.1 is critical for expression of 
the growth factor receptor CD115 (CSF-1R/M-CSFR) essential for monocyte development 
and survival16. Furthermore, PU.1-IRF8 heterodimer induces the KLF4 transcription factor, 
further driving monocyte-specific differentiation17,18. The GMP can give rise to the 
monocyte/macrophage and dendritic cell progenitor (MDP) characterized as 
CX3CR1+CD115+CD117+CD135(Flt-3)+Lin-19,20. MDPs can give rise to either the common 
DC precursor, CDP(CD115-, CD135+), restricted to generating DCs, or the common 
monocyte progenitor (cMoP)(CD115+, CD135-), that can directly give rise to Ly6C+ 
monocytes21–24.  
Additionally, the spleen has been identified as a site for extramedullary 
hematopoiesis. Stem cells from the bone marrow or fetal liver seed the splenic red pulp, and 
upon stress, differentiate and proliferate to generate a reservoir of Ly6C+ monocytes that 
then traffic to inflamed tissues en masse25,26.   
Murine monocytes subsets 
Morphologically, monocytes are described as having an irregular shape with 
membrane ruffling, an oval or kidney shaped nucleus and a high cytoplasm to nucleus 
ratio6,27. They can be active constituents in both inflammation and its resolution, contributing 
by acquiring cellular and pathogenic material and releasing chemo- and cyto-kines28,29.  
With the progression of lineage tracing techniques and characterization by 
polychromatic flow cytometry it has become increasingly clear that monocytes are not a 
homogenous population. Murine monocytes are divided into two subsets typically defined by 
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their expression of Ly6C. Ly6C expression is not restricted to monocytes, and has been 
shown to be expressed on non-cycling CD8+ T cells, involved in integrin interaction to aid in 
homing30. However, Ly6C is not expressed on human monocytes (discussed later), and as 
of yet, Ly6C in murine monocytes has no reported contribution to monocyte development or 
trafficking from the bone marrow and blood. This suggests that Ly6C function can either be 
compensated by another molecule(s), or that it contributes to monocyte processes not yet 
studied. The two murine subsets include the classical ‘inflammatory’ Ly6C+ (CX3CR1int, 
CCR2+, CD62L+) and the non-classical Ly6Clo (CX3CR1hi, CCR2-, CD11cmid, CD43+)21,31,32. 
Rather than having distinct precursors, emerging evidence strongly supports that circulating 
Ly6C+ monocytes can re-enter the bone marrow and differentiate into Ly6Clo monocytes, 
contingent on the transcription factor NR4A1 (Nur77)21,24,28,32,33. 
Beyond surface marker expression, differences between monocyte subsets include 
cellular size, longevity, homing and functional responses. Mature Ly6C+ monocytes have a 
shorter life-span, about 20-25 hours in circulation, and are slightly larger, 10-14µM, 
compared to Ly6Clo monocytes, which live for 5-7 days, and range from 8-12µM in size27,31. 
Classical monocytes are selectively recruited to tissues and can traffic to draining lymph 
nodes via high endothelial venules dependent on CD62L and CCR234–36. In accordance with 
their homing abilities, Ly6C+ monocytes are also capable of presenting antigen to naïve T 
cells. Furthermore, upon acute inflammation there is fast, robust Ly6C+ monocyte efflux from 
the bone marrow and splenic reservoirs26. In contrast, Ly6Clo monocytes primarily ‘patrol’ the 
vasculature by crawling along endothelial cells in blood vessels. Ly6Clo monocytes 
contribute to the resolution of inflammation by a secondary wave of recruitment that 
promotes angiogenesis and tissue remodeling28,29,37.    
Human monocytes subsets 
Classical and non-classical populations of monocytes also exist in humans and 
express comparable levels of CX3CR1 as in mice31. Additional markers for identification 
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include CD14 or CD16. CD14high monocytes resemble classical Ly6C+ monocytes, and 
CD16high are comparable to non-classical Ly6Clo monocytes38,39. These two populations are 
functionally similar to their murine counterparts; however, they differ in population frequency. 
In humans, 90% of circulating monocytes are ‘classical’, while in mice ‘classical’ and ‘non-
classical’ are nearly equally represented. Additionally, in humans, a small intermediate 
population exists, identified as CD14highCD16mid. In a more recent study performing single-
cell RNA sequencing on human peripheral blood monocytes, the intermediate population 
was further sub-divided into two separate populations with unknown functionality, to date.40 
Antigen Acquisition 
 Antigenic molecules – proteins, polysaccharides or lipids - originate from either the 
external environment (i.e. bacterial, fungal or viral antigen) or host (i.e. self-antigen). Self-
antigen can be cell-associated (intracellular or membrane-bound) from dying cells. However, 
cell-associated debris can also include foreign antigens, as in infection-induced 
apoptosis41,42. Professional phagocytes, and to some extent non-professional phagocytes, 
internalize, or endocytose, antigens as a means for host protection43,44. Endocytosis is the 
active formation of intracellular vesicles (endosomes) by the invagination of the plasma 
membrane, allowing the cell to engulf particles, vital micronutrients, as well as antigens. The 
internalization of apoptotic cells (along with cell-associated antigens), is a mechanistically 
distinct process of endocytosis and is therefore termed efferocytosis45,46.  
Mechanisms of efferocytosis 
The clearance of apoptotic cells is a complex process with redundancy in pathways. 
Nevertheless, it involves five key steps. First, the apoptotic cells themselves undergo 
alterations, for example by providing ‘find me’ signals such as increased carbohydrate, 
cholesterol, lipid or protein surface expression, redistribution, or secretion47,48. Most notable 
is the increased exposure of phosphatidylserine (PS) on the outer leaflet of the membrane 
bilayer49. Second is the recognition of apoptotic cells by the phagocyte. Scavenger receptor 
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(including, not limited to CD36, CD68, SRA) and adaptor molecules (Gas-6, 
thrombospondin) bind PS or other exposed ligands that either provide ‘eat me’ signals (i.e. 
PS exposure, calreticulin), and/or loss of ‘don’t eat me’ signals (i.e. CD47)48,50–52. 
Additionally, opsonization of apoptotic cells by complement (C1q, mannose binding lectin 
[MBL]) promote phagocytosis through calreticulin-CD91 interactions on the phagocyte53. 
Third is the adhesion of apoptotic corpses and the transduction of signaling pathways 
involved in cytoskeletal rearrangement - ‘tether and tickle’47. Candidate molecules for 
tethering include (but are not limited to) CD14 and TIM-454. The Rho family GTPases, such 
as Rac-1 and RhoG, then stimulate the uptake process55–58. Next is the endocytic ingestion 
via phagocytosis or a micropinocytosis-like process. Phagocytosis induces a zipper-like 
mechanism to ingest particles >0.5µM in diameter, while macropinocytosis ‘gulps’ 
extracellular milieu that can contain apoptotic blebs by creating membrane arm-like 
extensions45,46,59. The last step is endosome maturation that leads to the digestion of 
ingested material.   
Endosomal maturation and antigen processing 
The endocytic compartments along the cellular periphery that receive incoming cargo 
and fluid are the early endosomes (EE)60. The EE consists of tubular domains allowing for 
the recycling of content, and a central vacuolar domain61. As the vacuolar domain of the EE 
matures into the late endosome (LE) the endo-lysosome trafficking molecules Rab5/EEA1 
convert to Rab7/LAMP162. Microtubule networks transport the maturing endosome to the 
perinuclear region of the cell where lysosomal fusion can occur - the point of no return for 
cargo degradation63.  
Endosome maturation is accompanied with functional changes, most notable is the 
recruitment of the V-ATPase, consisting of a multi-subunit proton pump that drives 
acidification64. The mildly acidic EE (pH ~6.2) drops in pH as it matures into the LE (pH 
~5/5.5) and fuses with the lysosome (pH <5)65,66. Further regulation and offsetting 
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acidification of the endosome is contributed by the NADPH oxidase, localized in the EE 
upon invagination of the plasma membrane and replenished from a lysosomal pool with aid 
from SNARE proteins67,68. Comprised of the membrane subunits Cyba (p22phox), Cybb 
(NOX2/p91phox) and the catalytic subunits Ncf1 (p47phox), Ncf2 (p67phox), Ncf4 (p40phox) and 
Rac-1, the NADPH oxidase is involved in alkalization by the generation of reactive oxygen 
species (ROS)69. ROS can neutralize free hydrogen ions generated by the V-ATPase, as 
well as induce membrane permeability and the release of endosomal contents70,71.  
Careful control of pH at each stage of endosome maturation is critical for balancing 
maintenance with destruction of internalized content. Slightly acidic environments 
associated with the EE promote the dissociation of ligands from their receptors for recycling, 
as well as the activation of the exopeptidases (i.e. Cathepsins B and C) involved in peptide 
trimming64,72–74. The v-ATPase is also involved in lysosome fusion75. In contrast, LE or 
lysosomal compartments contribute to the localization and/or activation of endopeptidases 
such as AEP and Cathepsins D, H, L, S76.  Furthermore, lysosomal proteases are required 
for the cleavage and activation of endosomal TLRs77–79. Regulated processing antigenic 
peptides is also important in the context of antigen presentation, and is partly attributed to 
DCs being such efficient cross-presenters, discussed in a later section.  
Monocyte acquisition of apoptotic cells (cell-associated antigen) 
 Within tissues, macrophages and Batf3+ (CD8a+) DCs are known for their ability to 
engulf apoptotic cells, whereas IRF4+ DCs do not appear to exhibit this property80–82. 
Despite longstanding observations of monocytes as professional phagocytes, their ability to 
acquire apoptotic cells has not gained much attention. Early studies assessing monocyte 
efferocytosis are restricted by use of monocyte-derived macrophages differentiated in 
culture83. Nevertheless, this suggests efferocytosis is an inherent property of peripheral 
blood monocytes. Another early study that suggested monocytes can efferocytose assessed 
cytokine production by monocytes cultured with apoptotic cells. In that study, 
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thrombospondin-specific antibodies (which binds to the scavenger receptor CD36) altered 
the monocyte cytokine profile, indicating efferocytosis and consequent signaling84,85. 
However, engulfment of apoptotic cells was not directly assessed, and just physical 
interactions of the phagocytes with apoptotic cells can promote the release of anti-
inflammatory cytokines45. More recently, human monocytes from peripheral blood have been 
shown to efferocytose apoptotic neutrophils; however, in this study the CD16+ monocytes, 
correlating to murine Ly6Clo monocytes, had greater potential to efferocytose compared to 
the CD14+ (Ly6C+) monocytes86. As migration into tissues promotes the maturation of Ly6C+ 
monocytes, addressing the capacity of these tissue-resident cells to engulf apoptotic cells is 
of interest87.  
Presentation of Protein Antigen 
Myeloid APCs are considered the sentinels of the immune system for multiple 
reasons – they are strategically positioned at potential pathogen entry sites, high capacity 
for antigen capture, are dynamically responsive to environmental stimuli, and have the 
ability to engage the adaptive immune system via MHC molecules27,88. Their endocytic 
properties confer the generation of denatured, sequential peptide fragments required by T 
cells for recognition. The recognition of these peptide fragments, and consequent activation 
of either humoral (immunoglobulin) or cellular immunity, is dictated by how antigenic protein 
is seen by the APC.  
Endogenous antigen, such as from an infected cell, is processed and presented onto 
MHC Class I to engage CD8+ T cells (Figure 1-1A)89.  When professional phagocytes 
internalize exogenous antigen, such as opsonized bacteria, it is processed to be presented 
onto MHC Class II molecules, engaging helper CD4+ T cells (Figure 1-1B)90. However, 
there is another unique process in which exogenous particles are presented onto MHC 





Figure 1-1. Pathways of antigen presentation. (A.) Classical antigen presentation of 
endogenous antigen, such as from an infected cell, is processed through the immunoproteasome and 
peptide fragments are presented onto MHC Class I molecules to CD8+ T cells. (B.) Classical antigen 
presentation of exogenous antigen is restricted to professional antigen presenting cells, in which the 
process of endocytosis, such as receptor-mediated endocytosis of opsonized pathogens, shuttles 
antigen to a specialized compartment for processing and loading onto MHC Class II molecules for 
presentation to CD4+ T cells. (C.) Cross-presentation is largely restricted to dendritic cells and 
monocytes, in which internalized antigen, for instance infected apoptotic cells, are presented on MHC 
Class I molecules to present to CD8+ T cells. The intracellular mechanisms of cross-presentation are 



















APCs that are not directly infected to mount an immune response, and also critical 
for the maintenance of central and peripheral tolerance91,92.     
Mechanisms of cross-presentation 
While the pathways for classical antigen presentation are well-defined, there is much 
debate on the precise mechanisms of cross-presentation. There are two primary theories – 
the widely accepted ‘cytosolic’ as well as the ‘vacuolar’ pathways (Figure 1.2)92. A multitude 
of factors likely determine which pathway is predominantly utilized; for example, the nature 
and amount of the protein and therefore mechanism of uptake93,94. The multi-step process of 
cross-presentation begins once the antigen has been acquired within the endosome (Figure  
1.2, Step 1). Coordinated effects of recruited V-ATPase and NADPH oxidase generate 
optimal pH for limited proteolysis (Figure 1.2, Step 2)95. The partial degradation of 
internalized antigen by endosomal proteases must be tightly controlled to maintain T cell 
epitopes for downstream presentation, particularly with long peptides. This regulation is 
believed to be the limiting step in macrophage cross-presentation, and the reason DCs are 
so efficient at presenting antigen in comparison.             
 For cytosolic cross-presentation to occur, antigen is released from the EE into the 
cytosol (Figure 1.2, Step 3)96–99. Targeting antigen to early endosomes promotes cross-
presentation efficiency, with the belief that antigen degradation by lysosomal proteases is 
limited, and antigenic peptides are maintained98. The most convincing mechanism of 
antigenic release is that ROS generated from the NADPH-oxidase induces lipid peroxidation 
and a permeable membrane resulting in antigen leakage70. Once protein is in the cytosol, it 
can be ubiquitinated for degradation into peptide fragments by the inducible 
immunoproteasome (Figure 1.2, Step 4)96,100. The processed peptides can be translocated 




Figure 1-2 Cytosolic route of antigen cross-presentation. Cross-presentation is a multi-step 
process. 1.) Antigen is acquired through an endocytic process. 2.) Coordinated efforts of the V-
ATPase and NADPH oxidase regulate endosomal pH achieves partial degradation of proteins. 3.) 
Antigen is released from the endosome into the cytosol. 4.) Protein is ubiquinated and degraded by 
the immunoproteasome. 5.) Peptide fragments are transported into the ER and loaded onto MHC 
Class I molecules with aid from the peptide loading complex (PLC) and 6.) transported on the surface 
of the APC. 7.) Additionally, cross-presentation requires the upregulation of co-stimulatory molecules 















for MHC Class I loading on nascent molecules101,102. After transport, peptides are trimmed 
by ER or endosomal peptidases – ERAP1 or IRAP (Figure 1.2, Step 5)103–105. In contrast, 
vacuolar cross-presentation is independent of the immunoproteasome and TAP transport. In 
this pathway, exogenous proteins are degraded into peptide fragments by proteases within 
the endosome, namely cathepsin S94. MHC Class I molecules are delivered to the 
endosomes by clathrin-mediated endocytic recycling from the plasma surface, and the 
peptide loading complex are transported from the ER, mediated by Sec22b106.  
Regardless of pathway utilized, ultimate peptide loading onto MHC Class I molecules 
is achieved with help of the peptide loading complex, consisting of βm, calnexin, 
calreticulin, ERp57 and tapasin, which form a chaperone complex and trim the peptide to 
the necessary 8-10 amino acids107. Complexed peptide:MHC Class I traffics to the cell 
surface for presentation to CD8+ T cells (Signal 1) (Figure 1.2, Step 6). As all nucleated 
cells express MHC Class I, restricted and efficient T cell activation and differentiation 
resquires additional signals - co-stimulation (Signal 2) (Figure 1.2, Step 7) and secreted 
mediators (Signal 3) (Figure 1.2, Step 8), discussed in greater detail later.  
Ly6C+ monocytes as cross-presenters 
While all nucleated cells express MHC Class I, cross-presentation is restricted to a 
few select cell types. This is due to requirements encompassing endocytosis potential, 
careful antigen processing, as well as the expression of co-stimulatory molecules to activate 
CD8+ T cells. Further limitations in cross-presentation efficiency include type of antigen, 
tissue the APC is derived from, APC cell type and consequently pattern recognition receptor 
(PRR) repertoire, as well as variations in experimental design. DCs are the most described, 
and cross-presentation is predominantly a function of the CD8α+ (Batf3+) DC, which is able 
to cross-present both soluble and cell-associated antigen (Table 1)80,108. CD11b+ (IRF4+) 
DCs are also capable of presenting soluble antigens, but as they lack the ability to engulf 



























Monocyte-derived DCs have been shown to induce T cell proliferation, as a measure of 
cross-presentation, against both soluble and cell-associated antigens, suggesting this may 
be as a property of undifferentiated moncoytes109–113. Indeed, bone marrow and skin derived 
Ly6C+ monocytes have been shown to cross-present soluble antigens34,36. One study 
measuring cross-presentation of cell-associated antigen showed that Ly6C+ monocytes from 
the bone marrow did not activate CD8+ T cells; however, we know that extravasation into 
tissues promotes maturation of Ly6C+ monocytes, as well as their cross-presentation 
potential34,87,110.  Therefore, determining if tissue monocytes can cross-present cell-
associated has not been directly assessed. 
Toll-like Receptors (TLRs) 
In the context of antigen presentation, phagocytic APCs must be capable of 
discriminating self from non-self to avoid mounting potentially hazardous immune responses 
against autologous protein. This is achieved by the recognition of conserved pathogenic 
associated molecular patterns (PAMPs) by germ-line encoded PRRs114. PRRs are divided 
into four families, C-type lectin receptors (CLRs), NOD-like receptors (NLRs), RIG-like 
receptors (RLRs) and Toll-like receptors (TLRs)115. TLRs are transmembrane proteins that 
play critical roles in innate immunity, as evidenced by their evolutionary conservation from 
Drosophila to mammals116. TLRs’ strategic localization (surface- or endosome-bound), 
determined by their transmembrane domain, and cell type-specific expression enable the 
recognition of their cognate ligand in the appropriate context to regulate both innate and 
adaptive immunity115,117. Ultimately, ligation of TLRs stimulate gene transcription that 
promotes inflammation and tissue repair, and initiates adaptive immunity.  
TLR properties and localization 
To date, 12 murine and 10 human TLR members have been identified (Table 1-2)118. 
Focusing on murine receptors, the surface bound TLR2 senses bacterial lipopeptides and 




















diacylated lipopeptides119,120. Surface TLR5 senses bacterial flagellin121. TLR11 can sense a 
component of uropathogenic bacteria, or in cooperation with TLR12, profilin protein122,123. 
Within the endosomes, TLR3 senses dsRNA, TLR7/8 senses ssRNA, TLR9 senses 
hypomethylated CpG motifs, and TLR13 senses 23S ribosomal RNA124–127. Lastly, TLR4 
recognizing bacterial lipopolysaccharides is surface-bound with MD2, but can also be 
endocytosed and signal within the endosome128. TLRs are type I transmembrane proteins 
that consist of a leucine-rich repeat (LRR) domain involved in PAMP recognition and a 
cytoplasmic Toll/interleukin-1 receptor (TIR) signaling domain. Upon dimerization TIR 
signaling recruits specific adaptor molecules, primarily MyD88 (utilized by all TLRs with 
exception of TLR3) or TRIF (TLR3 and endosomal TLR4) that lead to downstream 
translocation of the transcription factors NF-κB, and/or IRF signaling129,130. Complex 
signaling pathways transduced through TLRs rapidly (peaking 3-6 at hours) induce the 
transcription and synthesis of proinflammatory cytokines and chemokines (CCL2, CCL4, 
TNF, IL-1, IL-6)131.  
To counter-balance potentially harmful excess cytokine production, TLR signaling is 
negatively regulated through several mechanisms. First, molecules such IRAK-M and  
SOCS-1 negatively regulate TLR signaling132,133. Additionally, upon ligation TLR mRNA 
transcript expression is down-regulated134 Lastly, alternative splicing of MyD88 from the long 
to short isoforms can limit inflammatory cytokine production135. 
As nucleotides can be derived from both foreign and host entities, the localization of 
TLRs that bind DNA and RNA motifs (TLR3, TLR7/8, TLR9, TLR13) must somehow be 
regulated. Stimulation with their ligands induce trafficking of these TLRs from the ER to 
endosomes via UNC93B1136. Cleavage with the endo-lysosome by cathepsin proteases 
allows association of TLRs with MyD88, required for functional signaling137. Therefore, their 
intracellular localization controls access of these receptors and serve as physical barriers to 
discriminate self from non-self117.   
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TLR enhancement of antigen acquisition  
 As critical components in the clearance of microbes, TLR signaling augments both 
the number of phagocytes (including monocytes) that can acquire antigen, as well as the 
amount of antigen acquired within any given cell. In part, enhanced phagocytosis is due to 
the upregulation of scavenger receptor gene expression induced by TLR-MyD88 
signaling138. However, phagocytosis can be rapid process, in some scenarios occurring 
within just five minutes. Therefore, short-term effects independent of gene expression can 
also modulate TLR-mediated phagocytosis. ERK has been implicated in cytoskeletal 
rearrangement required for phagocytosis, and in fact, phosphorylated ERK has been 
observed within fifteen minutes upon LPS activation139–141. Additionally, the active GTP-
bound Rac1 and Cdc42 aid in actin assembly during phagocytosis142,143. Within two minutes 
of LPS stimulation, Rac1 was observed in its active form, and within 30 minutes Cdc42 was 
GTP-bound140.   Additional post-translational modifications include phosphoinositide 3-
kinase (PI3K) mediated phosphorylation and recruitment of proteins to the cellular surface to 
aid in cytoskeletal rearrangements144,145.  
TLR initiation of adaptive immunity  
The recognition of pathogenic determinants, via TLRs, by the innate immune system 
sets in motion acquired immunity. TLR signaling has been shown to be involved in each 
step of cross-presentation – the regulation of endosome acidification through NADPH 
oxidase activity, the slowing of peptide:MHC Class I decay, the upregulation of co-
stimulatory molecules, and the trafficking of APCs to draining lymph nodes or the white pulp 
within the spleen146–149. Lastly, TLR signaling can initiate APC cross-priming, the production 
of soluble mediators that drive the CD8+ T cell cytotoxic differentiation (Signal 3). The most 




The immune-stimulatory environment determines the cross-presentation efficiency 
for a given APC type. While Batf3+ DCs are considered the most effective cross-presenters, 
in some scenarios, such as S. cerevisiae infection, splenic IRF4+ DCs are more efficient at 
inducing CD8+ T cell immunity152,153.  These differences in cross-presentation efficiency are 
due in part to each APC expressing a distinct repertoire of TLRs whose cis-activation are 
required for cytotoxic responses154. However, studies assessing the ability of Ly6C+ 
monocytes to cross-present when stimulated by TLR agonists have been limited, in which 
only LPS (TLR4) stimulated monocytes have been tested36. Therefore, a broader 
characterization of the effects of TLR ligation on monocyte cross-presentation is of interest 
to determine their role in initiating and supporting CD8+ T cell responses.  
Although TLRs represent one group of PRRs, they are of most interest in developing 
therapeutics. Other PRRs, such as NOD receptors have been shown to augment TLR 
responses, but there is limited data to suggest that they, or other PRRs, enhance cytotoxic 
immune responses in isolation155. As TLRs enhance cross-priming capacity, understanding 
TLR activation in APCs is important in improving immunogenicity through its adjuvant 
properties in vaccine design156. 
Scope of Project 
As described in the introduction, monocytes are myeloid phagocytes involved in both 
innate and adaptive immune responses. Researchers are reviving efforts to further 
understand the contribution monocytes have towards regulating host defense systems. With 
the discovery that monocytes can acquire, traffic and present soluble antigen to initiate 
cellular immunity, we had three main questions to explore the role of monocytes as antigen 
presenting cells in the context of cell-associated antigen:  
1) Can Ly6C+ monocytes acquire cell-associated antigen (apoptotic cells)? 
2) Can Ly6C+ monocytes cross-present acquired cell-associated antigen to activate 
CD8+ T cells?  
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3) Does TLR ligation regulate either efferocytosis and/or cross-presentation/cross-
priming of apoptotic cells by Ly6C+ monocytes?  
Ultimately, this document will begin to address how the inflammatory environment can 
uniquely and differentially regulate monocyte contribution to host defense, compared to 

























MATERIALS AND METHODS 
Mice 
CD45.1 and CD45.2 C57BL/6, C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1), TLR7-/-, 
CD14-/-, MyD88-/-, Batf3-/-, Ncf1-/- and C57BL/6-Tg(AOVA) 916Jen/J mice were purchased 
from Jackson Research Laboratories and bred in house.  Mice used for experiments were 6-
12 weeks of age and maintained in specific pathogen-free facility at National Jewish Health, 
an AALAC accredited institution and used in accordance with protocols approved by the 
Institutional Animal Care and Utilization Committee.   
Medias and Buffers 
For culturing cells, culture media consisted of DMEM (Fisher Scientific) complete 
media containing heat inactivated 10% fetal bovine serum (FBS)(Atlanta Biologicals), 2mM 
L-Glutamine, 100 U Penicillin and 0.1mg/ml Streptomycin. For cell enrichments, MACS 
buffer consisted of PBS pH 7.2 (ThermoFisher), 0.5% bovine serum albumin (BSA) (Sigma-
Aldrich) and 2mM EDTA (Invitrogen). For cell staining and FACS analysis, cells were 
suspended in Hanks Complete buffer, consisting of HBSS, 0.2% BSA 0.3mM EDTA 
(Invitrogen).   
Tissue Collection 
Spleens were obtained by dissection, followed by dicing and digestion with 1 ml of 
2.5 mg/ml Collagenase D (Roche) in RPMI (Fisher Scientific) for 20 min at 37ºC. To end 
enzymatic reaction, 100µl of 100mM EDTA (Invitrogen) was added. Single cell suspensions 
were obtained by pipetting digested tissue by Pasteur pipette and filtering through a 70µM 
nylon filter. Spleens were treated with 1mL of ammonium chloride lysing reagent (BD 





Isolation and Enrichment of Splenic Monocytes 
Ex vivo experiments requiring splenic monocytes were obtained by enrichment using 
a magnetic column-bead approach. First, a negative selection was performed, and in some 
experiments, this was followed by a positive selection.  Single cell suspensions were 
washed in MACS Buffer and incubated with PE- or biotinylated- conjugated mAbs against 
CD11c, CD3, Ly6G, B220 and NK1.1 for 30 min on ice, followed by two washes. If CD8α+ 
DCs were included in experiments, CD11c was not used for enrichment.  Cells were then 
incubated with anti-PE or anti-Biotin microbeads for 20 min on ice. After washing, cells were 
run through a magnetic LS column (Miltenyi Biotec) followed by several rounds of washing, 
collecting the negative flow-through fraction. Cells were either plated for experiments, or 
stained for fluorescent-activated cell sorting (FACS) sorting on the FACSAria Fusion (BD 
Biosciences). 
For positive enrichments, cells were then incubated with PE anti-Ly6C for 30 min on 
ice, washed, incubated with anti-PE microbeads, washed and again run on a LS column, 
collecting the magnetic-bound fraction.    
Preparation of Apoptotic Cells 
Thymocytes were extracted from C57BL/6 or AOVA mice. Single cell suspensions 
were obtained by mashing cells through a 40µM filter with a syringe plunger. When 
detection of apoptotic cells was desired, cells were labeled with 10µM CFSE (Invitrogen) for 
10 min at 37ºC. Incubation was stopped by adding 10% FBS, and washed twice in PBS. 
Apoptosis was induced by 60mJ UV radiation exposure and 1 hr incubation at 37ºC 
(StratLinker 1800, Agilent Technologies) or by 10 µM Dexamethasone treatment for 4 hrs at 
37ºC (Sigma-Aldrich). Apoptosis was confirmed by cellular staining and flow cytometric 






In vitro: The following TLR ligands (dose) were used for in vitro experiments, unless 
otherwise indicated: Pam3CSK4 (Pam3)(100pg/ml)(Enzo); LPS (10ng/ml)(E. Coli L8274 
Sigma-Aldrich); Resiquimoid (R848)(300ng/ml)(Enzo), ODN 1668 (CpG)(100ng/ml)(Enzo); 
ORN sa19 (sa19)(1µg/ml)(InvivoGen); CL264 (200ng/ml)(InvivoGen) Imiquimod (R837) 
(300ng/ml)(InvivoGen). Additional treatments included OVA257-264 (1µg/ml)(AnaSpec), anti-
mouse CD28 (1µg/ml)(Kedl lab), anti-mouse CD40 (1µg/ml)(IC10; Biolegend), recombinant 
CCL5 (100ng/ml)(Biolegend). 
In vivo: In vivo treatment of TLR ligands included Pam3 (10µg), LPS (5µg) and R848 
(50µg). 200ul of total volume was intravenously injected into mice through the tail vein.  
Antibodies and Cellular Staining 
Surface staining: For in vitro experiments, cells were released from culture plates by 
an ice incubation for 20 min and repeated pipetting.  
For most surface stains, single cell-suspensions in Hanks Complete were stained 
with directly conjugated antibodies (Abs) for 30 min on ice. The following anti-mouse Abs 
were used (clone, source): B220 (RA3-6B2; BioLegend), CD3 (17A2; BioLegend), CD8 (53-
6.7; eBio), CD11b (M1/70; BD), CD11c (N418; BioLegend), CD40 (1C10; eBio), CD45.1 
(A20; Invitrogen), CD45.2 (104; BioLegend), CD44 (IM7; BD),  CD69 (H1.2F3; eBio), CD80 
(16-10A1; eBio), CD86 (GL1; eBio), CD169 (mca947; Bio-Rad), F4/80 (BM8; eBio), Ghost 
Dye Red 780 (Tonbo), Ly6C (HK1.4; BioLegend), Ly6G (1A8; BioLegend), MHC Class I 
(AF6-88.5; BD), MHC Class II (M5/114.15.2; BioLegend), NK1.1 (PK136; eBio), 
SIINFEKL:H-2Kb (25-D1.16; eBio), Vαβ (Bβ0.1; BD).  
SIINFEKL:H2-Kb stain: For measuring ovalbumin peptide (SIINFEKL) expression, 
cells were incubated with anti-SIINFEKL/H-2Kb Biotin (25-D1.16; eBio) for 2 hrs at 37ºC. 
After washing, cells were stained with streptavidin-APC or PerCP-Cy5.5 with other 
necessary surface markers.  
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Annexin V stain: Annexin V (BD) detection was performed per BD protocol. Briefly, 
cells were washed in 1X Binding Buffer and resuspended at a concentration of 1 X 105 
cells/5µl Annexin V in 100µl 1X Binding Buffer for 15 min at RT. Cells were washed in 1X 
Binding Buffer for flow analysis. 
Membrane permeability stain: To measure cell membrane permeability as an 
indicator of cell viability, either DAPI (1µg/ml)(AnaSpec) or propidium iodide (PI) 
administered (5µl) immediately prior to running samples on the flow cytometer.  
Intracellular Staining: Following surface staining, cells were fixed and permeabilized 
using the Foxp3 Transcription Factor Staining Buffer Set and the provided protocol 
(eBioscience). Intracellular IFN  (XMG1.β; eBio) was used at a concentration of 1:50.  
Flow Cytometry 
Flow cytometry was performed on either the LSR II or LSR Fortessa (BD Biosciences) and 
data was collected using FACSDiva software (v8.0.1; BD Biosciences). Data was analyzed 
using FlowJo v10 software (Tree Star, Ashland OR).  
Phagocytosis Assays 
In Vivo: Mice received intravenous injections of either CFSE-labeled apoptotic cells 
(1X106) or YG-carboxylated beads (1:20 dilution) with or without TLR ligands in a total 
volume of 200µl. After one hour, determined by time-course analysis, spleens were 
harvested, and single-cell suspensions obtained for FACS analysis. PBS-treated mice were 
used as a negative control.  
Ex Vivo: Enriched Ly6C+ monocytes or CD8α+ DCs by negative selection were 
plated at 3X105 cells per well in a 96-well flat bottom plate for two hours at 37ºC, 5% CO2 in 
culture media. CFSE-labeled apoptotic cells (1X105) were added in combination with TLR 
ligands for one hour.  Then, the plate was placed on ice for 20 minutes, washed, and 
stained for flow cytometric analysis. For each assay, negative wells containing no CFSE-




Enriched monocytes were plated at 0.5X106 in a 100 µl bubble of culture media onto 
MatTek 35mm glass bottom dishes for 2 hrs at 5% CO2 and 37ºC. CFSE-labeled apoptotic 
thymocytes were added and co-cultured for 1 hr. Non-ingested thymocytes were removed 
with PBS wash. Cells were stained with PE anti-mouse Ly6C for 20 min at 5% CO2 and 
37ºC, and fixed with Fixation/Permeabilization buffer (eBioscience) for 30 min at room 
temperature. Z-stack images were taken using a Zeiss LSM700 Confocal with Zen software. 
Magnification is X 100. Images were analyzed using Fiji software157.  
pHrodo Bead Coupling 
0.2 µM yellow-green (YG) carboxylated beads were gently mixed with protein at 
37ºC for 2 hrs. After, beads were washed twice at 10,000 x g for 5 min and decanted. The 
pellet was resuspended with pHrodo succinimidyl ester (SE) (Invitrogen) and gently mixed at 
37ºC for another 2 hrs, followed by multiple washes.  
Peptide Presentation Assay 
Negatively enriched monocytes (3X105) were plated in a 96-well flat-bottom plate for 
one hour in culture media. Then AOVA apoptotic cells were added with or without TLR 
ligands. After an 18 hr incubation, cells were stained with biotinylated 25-D1.16 antibody for 
one hour at 5% CO2 and 37ºC. The plate was washed and incubated with streptavidin 
conjugated with either APC or PerCP-Cy5.5. Analysis was performed by flow cytometry. 
Wells containing no apoptotic cells with antibody stain were used as a negative control, and 
wells containing OVA257-264 (1µg/ml) were used as a positive control.  
Preparation of Transgenic CD8+ OT-1 T cells 
Spleens from CD45.1+ OT-1 transgenic mice were mashed through a 40µM filter 
using a syringe plunger, washed, and vortexed for 15 s in 1X ammonium chloride lysing 
reagent (BD Biosciences, San Jose, CA). After immediate washing in MACS buffer, cells 
were incubated in biotin anti-mouse CD3 for 30 min on ice, washed, and then incubated in 
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anti-biotin microbeads for 20 min. Cells were then run through a magnetic LS column per 
protocol (Miltneyi Biotec), collecting the positive, bound fraction by plunging. They were 
stained with 10µM CFSE in PBS for 10 min at 37ºC and washed in MACS buffer, followed 
by wash in culture media. Greater than 90% purity was confirmed by FACS analysis (Figure 
3-11B).   
T Cell Proliferation Assay 
For T cell proliferation assays, negatively enriched and either sorted or positively 
enriched Ly6C+ monocytes or CD8α+ DCs from CD45.2+ congenic mice were plated at 
7.5X103 or 3X105 cells per well, in a 96-well round bottom plate, respectively. AOVA 
apoptotic cells (1 apoptotic cell: 1 Ly6C+ monocyte) and purified CD45.1+ CFSE-labeled OT-
1 T cells (1X105) were added to the culture, plus TLR ligands. After 72 hours at 37ºC, 5% 
CO2, the plates were washed and stained for flow cytometric analysis. Proliferating T cells 
were considered CD45.1+CFSE+CD8+.  
For measuring intracellular IFN , cultures were assessed on day 5. Cells were 
incubated with 5X104 MHCII+ splenocytes, 10µg/ml Brefeldin A (BFA)(eBio) and 1µg/ml 
OVA257-264 (AnaSpec) at 37ºC, 5% CO2 for five hours. Then, cells were stained for surface 
markers, followed by intracellular stain.  
For measuring T cell proliferation in the absence of antigen-presenting cells, 96-well 
flat bottom plates were coated with anti-mouse CD3 (200ng/well) (17A2; eBio) overnight. 
The following day, plates were washed and CFSE-labeled OT-1 T cells added with TLR 
ligands for 72 hours at 37ºC, 5% CO2.  
Secreted Cytokine Measurements 
ELISA: Supernatant from T cell proliferation assays after 72 hours was collected for 
Mouse IFN gamma uncoated ELISA kit (Invitrogen). Assays were performed per 
manufacturer’s protocol. ELISA plates were read at 450 nm on Epoch 2 spectrophotometer 
(BioTek), using Gen5 software (BioTek) for data collection and analysis.  
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Membrane cytokine array: FACS sorted Ly6C+ monocytes (2X105) were plated in a 
96-well flat-bottom plate with either PBS, Pam3 or R848, in triplicate. After 18 hours, 
supernatants were pooled for each experimental group for the Mouse Cytokine Array Panel 
A (R and D Systems). Assay was performed per manufacturer’s instructions. Membrane was 
photographed on the ChemiDoc MP Imaging System (BioRad). 
In Vivo Cytotoxic T Cell Assay 
One day after OT-I cell adoptive transfer, WT or Batf3-/- mice were administered by 
intravenous delivery of AOVA apoptotic cells ± LPS or R848. Five days after immunization, 
CD45.1 WT and CD45.2 AOVA splenic target cells were labeled with CFSE and injected 
intravenously at a 1:1 ratio. The following day, spleens were harvested as described and 
specific killing of adoptively transferred CFSE+ were assessed by flow cytometry.  
RNA Isolation and Sequencing 
Negatively enriched splenic Ly6C+ monocytes or CD8α+ DCs were stained for FACS 
sorting on the FACSAria Cell Sorter. Additionally, from the Jakubzick lab alveolar 
macrophages from lung lavage were FACS sorted158. RNA was isolated from pure 
populations using the RNeasy Mini Kit (Qiagen). The isolated total RNA was processed for 
next-generation sequencing library construction as developed in the NJH Genomics Facility 
for analysis with a Life Technologies (Carlsbad, CA, USA) ion proton next-generation 
sequencing platform. A modified Clontech SMARTer Ultra Low Input RNA Kit for 
Sequencing - v3 (Mountain View, CA, USA) and modified Kapa Biosystems (Wilmington, 
MA, USA) KAPA Hyper Prep Kit was used to primarily target all polyA RNA. Briefly, library 
construction started from isolation of total RNA species, followed by mRNA (poly-A) 
isolation, 1st and 2nd strand cDNA synthesis, adapter ligation, amplification and bead 
templating. Once validated, the libraries were sequenced as barcoded-pooled samples on a 
P1 ion proton chip, as routinely performed by the NJH Genomics Facility. Heat maps were 
27 
 
generated from transcript per million (TPM) count reads using the Morpheus software 
(https://software.broadinstitute.org/morpheus/) from the Broad Institute. 
Statistical Analysis 
Statistical analysis was conducted using Prism software (version 7.0; GraphPad). All results 
were expressed as the mean and standard error of the mean (SEM). Statistical tests were 
performed using either a two-tailed unpaired Students t-test, or one-way ANOVA with 
multiple comparisons comparing the mean of each column with the mean of every other 
column. A value of p ≤ 0.05 was considered statistically significant. *p ≤ 0.05, **p ≤ 0.01, 
































LY6C+ MONOCYTES CAN ACQUIRE AND CROSS-PRESENT CELL-ASSOCIATED 
ANTIGEN TO INITIATE CD8+ T CELL PROLIFERATION1  
Introduction 
Monocytes have long been described as professional phagocytes. Yet, there is a 
surprising shortage of literature addressing the ability of ‘tissue resident’ monocytes, defined 
as Ly6C+ monocytes that have at some point extravasated into tissues, to engulf apoptotic 
cells (efferocytose). Nevertheless, interest in Ly6C+ monocytes as effector cells is growing, 
and in fact they have recently been shown to present soluble antigens to induce CD8+ T cell 
proliferation. Like Ly6C+ monocyte efferocytosis, there is limited evidence of ‘tissue resident’ 
monocytes ability to cross-present antigen associated with apoptotic cells to CD8+ T cells. 
Therefore, I aimed to further describe monocytes as antigen presenters, specifically 
determining if they can initiate CD8+ T cell adaptive immune responses against apoptotic 
cell derived antigens. Apoptotic cell-associated antigen is of interest as apoptosis can result 
from a myriad of causes including direct pathogen infection, inflammatory or traumatic 
damage, as well as the process of tumor maturation.  
In this chapter, experiments are presented in a linear fashion to identify the potential 
of Ly6C+ monocytes at each step of cross-presentation - from the initial step of antigen 
acquisition to downstream T cell proliferation (see Figure 1.2). Additionally, experiments 
were performed in parallel with other myeloid phagocytes as comparisons – macrophages, 
known to robustly engulf apoptotic cells, and CD8α+ DCs, capable of acquiring and cross-
presenting cell-associated antigen80,108. In this chapter, I made the observations that Ly6C+ 
monocytes can engulf apoptotic cells, equivalently to CD8α+ DCs. Additionally, I found that a 
                                                          
1 With pu lisher’s per issio , portio s of this hapter have ee  odified fro  the origi al arti le Ly6C+ 
monocyte efferocytosis and cross-presentation of cell-asso iated a tige s . “R Larso , “M Atif, “L Gi i gs, 
SM Thomas, MG Prabagar, T Danhorn, SM Leach, PM Henson and CV Jakubzick. Cell Death and Differentiation 
(2016) 23, 997-1003. 
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sub-population of Ly6C+ monocytes that express co-stimulatory molecules also retain 
antigenic peptides to present peptide: MHC Class I complexes on their surface. Lastly, I 
demonstrated that Ly6C+ monocytes can present antigen to initiate CD8+ T cell proliferation.  
Results 
How are murine splenic Ly6C+ monocytes identified?  
 As multiple myeloid cell types are derived from common ancestors, there is much 
overlap in surface marker expression. However, combining polychromatic staining strategies 
with light scatter by flow cytometry can easily separate these populations for identification. 
The focus of these studies is on Ly6C+ monocytes. I focused on murine splenic monocytes 
as a primary cellular source in our studies for three reasons – primary cells are more 
biologically relevant than immortalized monocyte cell lines such as THP-1 or U937, the ease 
of genetic manipulation by use of commercially available mouse strains and because the 
spleen contains a large pool of monocytes. Within the splenic hematopoietic population 
(CD45+), marginal zone macrophages (MZM), red pulp macrophages (RPM) and 
metallophilic macrophages (MM) were excluded by use of F4/80 and their high side scatter 
(SSC) (Figure 3-1A [highlighted in blue], B). For simplicity, these will further be referred to 
as F4/80+ Mac. Of the dendritic cell populations, plasmacytoid DCs are identified as 
B220+Ly6C+, whereas classical dendritic cells as CD11chiMHCIIhi - further differentiated by 
CD8α+ (Batf3+ DCs) and CD11b+ (Irf4+ DCs) [highlighted in black]. Lastly, both Ly6Chi 
(CD11c-) and Ly6Clo (CD11cmid) monocytes express CD11bhi and are SSClo [highlighted in 
red].  
Can Ly6C+ monocytes acquire cell-associated antigen? 
To determine if Ly6C+ monocytes can acquire cell-associated antigen, I first 
developed a protocol to generate apoptotic cells. Murine thymocytes were used as a primary 
cellular source for apoptotic cells. UV irradiation, rather than biological or chemical 




Figure 3-1. Gating strategy for identification of murine splenic myeloid APCs by flow 
cytometry. Whole digested spleens were extracted from naïve C57BL/6 (WT) mice. Live cells 
determined by SSC-A and FSC-A were gated on, followed by doublet exclusion (SSC-W and CD11b). 
(A.) Dot plots identify CD45.1+ cells, subsequently gated to identify macrophages (F4/80+)(blue dot 
plot), conventional DCs (CD11chiMHCIIhi)(black dot plot) and monocytes (SSClo, CD11b+)(red dot 
plot). (B.) Contour plot of splenic myeloid phagocytes, as gated on in A, distinguished by both size 




apoptosis to avoid unintentional transfer of apoptotic-inducing reagents159,160. To confirm 
cells were apoptotic without becoming secondarily necrotic, cells were surface stained for 
Annexin V (binds to translocated phosphatidylserine [PS], indicating apoptosis) and 
propidium iodide (PI)(membrane impermeant dye that intercalates with DNA and RNA, 
indicating necrosis)161. Upon time-course analysis of UV-irradiated thymocytes, there was an 
overall decrease in PI(-) cells cultured in PBS compared to culture media conditions (Figure 
3-2A, B). Both culture conditions decreased PI(-) cells after 2 hours of incubation (Figure 3-
2A, B). Measuring Annexin V expression on PI(-) cells from the media culture at either one 
or two hours, there was a clear shift within the first hour of incubation compared to cells at 
time zero, which only slightly increased after two hours of incubation (Figure 3-2C). 
Therefore, UV-irradiated cells cultured in media for one hour was the standard for 
generating apoptotic cells throughout these studies, as this condition induced apoptosis with 
the least necrosis. 
Initial experiments addressed the ability of Ly6C+ monocytes to acquire apoptotic cells 
(efferocytose) in vivo. C57BL/6 (WT) mice were intravenously injected with CFSE- labeled 
apoptotic thymocytes and spleens were harvested after one hour for flow cytometric 
analysis. To demonstrate our methods were in line with previously published data, I 
evaluated the ability of splenic Batf3+ (CD8+) DCs and Irf4+ DCs (CD11b+) to efferocytose 
(Figure 3-3A). As previously described CD8+ predominantly acquired apoptotic thymocytes 
compared to CD11b+ DCs80,82. 
For a more comprehensive analysis of immune cells within the spleen that are 
capable of efferocytosis, I examined whole spleens from mice treated with CFSE-apoptotic 
thymocytes. Primary gates were drawn on total CFSE(+) events (Figure 3-3B, left panel). 
Within the CFSE(+) population there were CD8+ DCs, Ly6C+ and Ly6Clo monocytes, 




Figure 3-2. Methods for induction of apoptosis on murine thymocytes. Mouse 
thymocytes were extracted and single cell suspensions obtained. Cells were UV irradiated at 60mJ 
and cultured at 37ºC in either PBS or culture media for the indicated time points. (A) Dot plots show 
non-necrotic cells identified as propidium iodide negative (PI-), quantified in (B). (C) Histogram plot 
shows Annexin V staining on PI- thymocytes from media cultures, measured over indicated times. 
Graph displays quantification of mean fluorescence of Annexin V stain. Data are representative of 








Figure 3-3. Numerous splenic cell populations are capable of efferocytosis, including 
Ly6C+ monocytes. WT mice were treated intravenously with CFSE-labeled apoptotic thymocytes 
for one hour.  Spleens were harvested for FACS analysis and efferocytosis determined by CFSE 
positivity. (A) Dot plots identify splenic DCs as CD11chi, further subdivided by CD8 expression to 
identify CD8α+ and CD11b+ (CD8α -) DCs. (B) Dot plot (left panel) represent total splenic population, 
gating on CFSE+ cells. Back gates determine CFSE+ cells consisted of DCs, macrophages, 


















As I observed that Ly6C+ monocytes can indeed acquire apoptotic thymocytes, I next 
wanted to measure their efficiency compared to other efferocytic phagocytes. Splenic 
macrophages and CD8α+ DCs were used as comparisons. Measuring efferocytosis of 
CFSE-labeled apoptotic thymocytes in vivo after an hour timepoint I saw rapid CFSE 
positivity in 24.8% of the CD8+ DCs (CD11chiMHCIIhi), and 47.4% of F4/80+ macrophages 
(Figure 3-4A top and middle panels, respectively). Interestingly, 17.7% Ly6C+ monocytes 
were also capable of efferocytosis under non-inflammatory conditions (Figure 3-4A bottom 
panels). Similarly, when quantifying the total number of splenic phagocytes that were 
CFSE(+), macrophages displayed the greatest number. However, the total number of Ly6C+ 
monocytes that were CFSE+ was comprable to CD8α+ DCs (Figure 3-4B). Furthermore, 
measuring the mean fluorescence intensity (MFI) of the FITC channel, amounts of apoptotic 
cellular material ingested on a per cell basis was determined. As expected, macrophages 
engulfed large amounts; however, monocytes and DCs had near overlapping MFIs (Figure 
3-4C). This data supports that monocytes are efficient phagocytes, comparable to CD8α+ 
DC.   
Next, I wanted to confirm that Ly6C+ monocyte efferocytosis was not limited to the 
method by which apoptosis was induced (UV-irradiation). To test this, thymocytes were 
cultured with dexamethasone (Dex) for 4hr at 37ºC, known to induce apoptosis of 
thymocytes by disrupting mitochondrial structure162. Mice treated with Dex-apoptotic 
thymocytes showed similar efficiency of efferocytosis by monocytes as those receiving UV-
apoptotic cells (15.6% and 11.4%, respectively) (Figure 3-5A).  
To determine if efferocytosis is an inherent property, splenic monocytes were 
enriched by negative selection and plated into a 96-well flat-bottomed plate. After allowing 
monocytes to settle and adhere for two hours, CFSE-labeled apoptotic thymocytes were 
added to the culture for an hour, at which time efferocytosis was measured. As in vivo 






Figure 3-4. Splenic Ly6C+ monocytes acquire apoptotic cells in vivo, comparably to 
CD8α+ DCs. WT mice were treated intravenously with CFSE-labeled apoptotic thymocytes (Apop). 
Control mice received no cells (PBS). After one hour, spleens were collected and analyzed by flow 
cytometry. Efferocytic CD8α+ DCs (CD11chi MHCIIhi), F4/80+ macrophages and Ly6C+ monocytes 
were determined as CFSE+. (A.) Dot plots display gating strategy to determine percentages of CFSE+ 
DCs (top panels), macrophages (middle panels) and Ly6C+ monocytes (lower panels) treated with 
either PBS or Apop, quantified on right (B.) Total number of splenic CFSE+ CD8α+ DCs, 
macrophages and Ly6C+ monocytes. Numbers were determined by multiplying percentage values of 
efferocytic cells (A) by hemocytometer cell counts from whole spleen. (C.) Histogram plot (left) shows 
CFSE mean fluorescence intensity (MFI) of untreated monocytes (grey), CD8α+ DCs (blue), 
macrophages (black) and Ly6C+ monocytes (red). Quantification displayed in bar graph (right). Data 





Figure 3-5. Ly6C+ monocytes engulf apoptotic microvesicles (<1.0 µM). (A.) WT mice 
were intravenously injected with PBS or CFSE labeled apoptotic thymocytes induced by either UV 
radiation (UV) or Dexamethasone (Dex) treatment. After one hour, efferocytosis by monocytes was 
determined by CFSE+ using flow cytometry. Graph displays percentage of Ly6C+ monocytes that are 
CFSE+. (B.) Splenic monocytes from WT mice were enriched by negative selection and plated in a 
96-well flat-bottomed plate for 2 hrs. CFSE-labeled apoptotic cells were then co-cultured for one hour 
and efferocytosis assessed by flow cytometry. Graph displays percentage of CFSE+ monocytes (C.) 
Representative image of co-cultures from ( B) were fixed and stained with phycoerythrin(PE)-Ly6C 
(red) and DAPI. Z-stack images were obtained to ensure ingestion of apoptotic cell/pieces (green). 
Scale bar is equal to 3.6µM. (D.) PBS, CFSE-labeled apoptotic cells or 0.2µM, 0.5µM, 1.0µM and 
2.0µM YG-carboxylated beads were intravenously injected into WT mice. After one hour, spleens 
were harvested to measure apoptotic cell or bead uptake by positive expression in the FITC channel 
using flow cytometry. A, D consisted of two independent experiments with 3-4 mice per group. B, 
represents three independent experiments with 4-5 replicates. C is a representative image from three 













being CFSE(+) (Figure 3-5B). It is notable that the proportion of CFSE+ monocytes is higher 
compared to in vivo studies. This could be explained by unintentional activation of the 
monocytes through the enrichment process, and/or by increased accessibility to the 
apoptotic cells. To visualize the physical interactions of monocytes with apoptotic cells and 
confirm actual engulfment (rather than adherence), Z-stack images were taken of ex vivo 
monocytes co-cultured with apoptotic thymocytes. Ly6C+ monocytes (red) appear to ingest 
apoptotic microvesicles (green) that are approximately one micron or smaller (Figure 3-5C).  
With the visual observation that Ly6C+ monocytes engulf apoptotic cell pieces 
approximately one micron in size, I wanted to expand upon this by measuring endocytosis of 
beads of a given diameter. WT mice were treated intravenously with fluorescently labeled 
(YG)-carboxylated beads ranging from 0.2 to 2.0 µM in diameter163. After an hour post 
injection, I saw that splenic Ly6C+ monocytes preferentially engulfed beads 1.0 µM or 
smaller in size, consistent with our previous ex vivo images (Figure 3-5D).  
To further characterize the ability of monocytes to efferocytose, RNA transcript 
expression of naïve cells was assessed. Naïve WT splenic Ly6C+ monocytes and CD8α+ 
DCs were negatively enriched and FACS sorted to obtain pure populations. RNA extracts 
were acquired for RNA-sequencing. Additionally, RNA-sequence data from alveolar 
macrophages was obtained from the Jakubzick lab158. Selected transcripts for scavenger 
receptors, adaptor proteins and negative regulators of efferocytosis were evaluated and 
arranged in a heat map, depicting relative gene expression for each row (Figure 3-6A). Of 
the selected scavenger receptors, macrophages had relative highest expression for most 
molecules, as predicted. However, while both Ly6C+ monocytes and CD8α+ DCs engulf 
equivalent amounts of apoptotic cells (as identified by MFI) transcript profiling suggests they 
do so by different mechanisms, in which DCs may utilize CD36, while monocytes use CD14, 
CD68 and/or Scara1. Broadly, monocytes have an intermediate phenotype of adaptor 





Figure 3-6. Naïve splenic Ly6C+ monocytes display unique transcript pattern of 
scavenger receptors, distinguishable from CD8α+ DCs and macrophages. (A.) CD8α+ 
DCs and Ly6C+ monocytes from WT spleens were negatively enriched and FACS sorted in triplicates. 
RNA from these pure populations was obtained for RNA sequencing. Alveolar macrophages were 
obtained by lung lavage and FACS sorted in triplicates for RNA-sequencing and analysis. Heat map 
was generated by the web-based Morpheus tool and displayed as row scaled data where blue and 
red indicate relative low and high transcript expression, respectively. Lowest and highest transcript 
per million count reads for each gene across samples is listed in parenthesis on right. (B.) WT and 
CD14-/- mice were treated intravenously with CFSE-labeled apoptotic cells for one hour, after which 
monocyte efferocytosis was measured by CFSE expression. Histogram plot shows mean 
fluorescence of CFSE in WT monocytes (black outline) overlaid with CD14-/- monocytes (blue shaded 















coloration can skew one’s interpretation of results, transcript per million counts of the 
highest and lowest expression for each gene are listed to the right.  
As monocytes express high levels of CD14 compared to other myeloid phagocytes, I 
performed preliminary experiments addressing the potential dependency of CD14 is for 
monocyte efferocytosis. In vivo treatment with CFSE-labeled apoptotic thymocytes into WT 
and CD14-/- mice showed no impairment of monocyte efferocytosis in the absence of CD14 
(Figure 3-6B). While this suggests that CD14 is not required for monocyte efferocytosis, 
there could very well be compensatory mechanisms. More experiments are needed to 
delineate specific mechanisms and the possible involvement of other scavenger receptors, 
such as Scara1, in monocyte efferocytosis. 
Combined, these studies show that in addition to CD8α+ DCs and macrophages, 
Ly6C+ monocytes acquire cell-associated antigen (apoptotic cells). As a means for 
combating potential pathogenic threats myeloid APCs have two approaches of processing 
antigen upon internalization – rapid antigen degradation to destroy potential pathogens 
(macrophages) or retainment of antigen for peptide presentation and initiation of an adaptive 
immune response (DCs)164,165. Therefore, I wanted to characterize downstream processing 
of antigen by Ly6C+ monocytes.  
Do Ly6C+ monocytes preserve antigenic peptides for presentation? 
 To initially determine how Ly6C+ monocytes process internalized antigen, I 
measured the acidification/alkalization and proteolytic enzyme potential by naïve transcript 
expression, comparing Ly6C+ monocytes to CD8α+ DCs and alveolar macrophages. RNA 
sequence analysis from naïve FACS sorted cells identified alveolar macrophages as having 
the greatest total expression of v-ATPase subunits compared to CD8α+ DCs, as expected. 
Ly6C+ monocyte v-ATPase transcript expression showed an intermediate phenotype, closer 
in line with the CD8α+ DCs (Figure 3-7A). Next, I looked at transcript of the NADPH oxidase 




Figure 3-7. Ly6C+ monocyte transcript expression profile suggests limited 
acidification and proteolysis. Spleens from WT mice were harvested, and CD8α+ DCs and 
Ly6C+ monocytes were negatively selected for. Pure populations were obtained by FACS sorting and 
RNA extracted to perform RNA sequencing. Alveolar macrophages were obtained by lung lavage and 
FACS sorted for RNA-sequencing. Heat maps was generated by the web-based Morpheus tool and 
displayed as row scaled data where blue and red indicate relative low and high transcript expression, 
respectively. Lowest and highest transcript per million count reads for each gene across samples is 
listed in parenthesis on right. Heat maps represent triplicate samples for each cell type of genes 

















alveolar macrophages (Figure 3-7B). Lastly, transcript expression of endosomal cathepsin 
proteases was assessed (Figure 3-7C). Alveolar macrophages expressed very high levels 
of all but one – Cathepsin E (Ctse). Ly6C+ monocytes had higher expression of some 
cathepsins compared to CD8α+ DCs, but significantly lower than alveolar macrophages. 
Noteworthy, monocytes expressed minimal transcript for Cathepsin D (Ctsd), the classical 
lysosomal endoprotease166,167. While transcript expression may serve as a starting point in 
elucidating function, non-transcriptional events, such as protein recruitment ultimately 
control acidification/ alkalizination168,169. Therefore, endosomal pH was directly measured by 
using pHrodo dyes which increase fluorescence as the surrounding environment acidifies170. 
To determine the relative endosome acidity upon antigen acquisition, mice were treated 
intravenously with pHrodo-labeled YG-carboxylated beads for one hour. The pHrodo 
intensity of bead(+) myeloid splenocytes was assessed, and as expected, macrophages 
were pHrodobright, whereas CD8α+ DCs were pHrodolo (quantified MFI of 1.5^4 and 6.6^2, 
respectively), in line with v-ATPase transcript expression (Figure 3-8). Interestingly, Ly6C+ 
monocytes also had pHrodolo intensity (MFI 2.9^2), comparable to DCs. This study in 
combination with the previously assessed transcript data suggests the near-neutral 
monocyte endosomal pH is likely due to the combination of low v-ATPase and high NADPH 
oxidase transcript expression.  
The ultimate outcome of limited antigen processing is the presentation of peptide 
onto MHC molecules. With the observation that monocytes have a relative neutral 
endosomal pH, I next wanted to determine the efficiency of monocytes to cross-present cell-
associated antigen by measuring peptide:MHC Class I complexes on their surface. For the 
remaining studies, only CD8α+ DCs were used as a positive comparison, due to their known 
ability to cross-present cell-associated antigen. First, I evaluated the expression of genes 
that are involved in peptide loading by RNA sequencing on FACS sorted naïve Ly6C+ 






Figure 3-8. Splenic Ly6C+ monocytes have similar endosomal pH as CD8α+ DCs in 
vivo. WT mice were intravenously injected with 0.2µM pHrodo Red labeled YG-carboxylated beads. 
After one hour, spleens were harvested for FACS analysis. Histogram plot (right) displays mean 
fluorescence intensity of PE channel (pHrodo) overlaying CD8α+ DCs (blue), F4/80 macrophages 
(black) and Ly6C+ monocytes (red) that were FITC(bead)+. Lymphocytes (bead-) were used as a 
negative control. MFI of PE channel is plotted in bar graph (left). Data are representative of two 
















Class I, Tapbp, TAP1 and TAP2 - involved in either peptide transport from the cytoplasm to 
the endoplasmic reticulum or components of the peptide loading machinery107. When 
comparing transcript per million (TPM) count reads there was comparable RNA expression 
of each of these genes between the DCs and monocytes (paired t test p=0.498) (Figure 3-
9A).  
 Next, I measured peptide:MHC Class I complex on the surface of monocytes. 
Negatively enriched monocytes were co-cultured with OVA+ apoptotic cells (AOVA) or 
OVA257-264 (SIINFEKL) peptide for 18 hours171. Using an antibody that specifically recognizes 
SIINFEKL bound to MHC Class I (25-D1.16), cross-presentation was measured by flow 
cytometry172. Monocytes have a short half-life, particularly in culture conditions, so DAPI 
stain (membrane impermeant dye which binds to intracellular DNA) was used to eliminate 
cells with discontinuous membranes, suggesting cell death. The total live (Dapi[-]) monocyte 
population from AOVA treatment displayed only slight surface expression of the 
peptide:MHC Class I complex; however, the 25-D1.16 antibody has reported low sensitivity 
(Figure 3-9B, D)172. To further investigate the ability of monocytes to cross-present, I 
evaluated typical co-stimulatory molecules and MHC protein expression on total DAPI(-) 
monocytes. Within the Ly6C+ monocyte population, there was a subset that expressed 
higher levels of MHC Class I and II, CD40, CD80 and CD86 (Figure 3-9B top panels). 
Interestingly, within the AOVA experimental group, monocytes that were positive for these 
co-stimulatory and MHC molecules had observable surface expression of peptide:MHC 
Class I compared to the total monocyte population (Figure 3-9 C lower panels, D). This 
suggests that subsets of Ly6C+ monocytes have distinct functions including but not limited to 
the presentation of antigen (by providing Signal 1 and Signal 2) - a topic of current 




Figure 3-9. A subpopulation of co-stimulatory+ Ly6C+ monocytes cross-present OVA 
peptide in vitro. (A) Spleens from WT mice were harvested, and CD8α+ DCs and Ly6C+ 
monocytes were negatively selected for. Pure populations were obtained by FACS sorting and RNA 
extracted to perform RNA sequencing. Graph displays average transcript per million reads, averaging 
triplicate samples for each cell type. (B) Enriched splenic monocytes were co-cultured with either 
PBS (grey shaded line), AOVA apoptotic cells (black line) or SIINFEKL peptide (OVA257-264) (black 
dashed) for 18 hrs, and then analyzed by flow cytometry. Gating on live monocytes (DAPI-), 
histogram plot displays mean fluorescence of SIINFEKL peptide bound to MHC Class I (H2-Kb). (C) 
From (B), live monocytes were further sub-gated on MHC Class I, MHC Class II, CD40, CD80 and 
CD86 (top panels). Histogram plots (bottom panels) show co-stimulatory+ populations (blue) overlaid 
on total live monocytes (black) displaying surface peptide:MHC Class I expression. (D) Bar graph 
shows quantification of peptide:MHC Class I MFI from (A) and (C). Data are representative of 1-4 






I wanted to further elaborate on the notion of monocyte subsets responsible for cross-
presentation/priming. For this, negatively enriched monocytes were plated and co-cultured 
with or without apoptotic thymocytes. Monocytes cultured at 4ºC were included as a naïve 
control. After 18 hours, surface co-stimulatory molecule expression was assessed by flow 
cytometry. In this experiment, MHC Class Ihi monocytes (blue) were also positive for CD40, 
CD80 and in part MHC Class II (Figure 3-10). Conversely, MHC Class Ilo monocytes were 
negative for each co-stimulatory molecule tested, overlapping monocytes incubated at 4ºC. 
This trend was observed whether monocytes were treated with apoptotic thymocytes or not, 
suggesting the process of plating and culturing monocytes ex vivo promote co-stimulatory 
molecule upregulation. However, the presence of apoptotic cells (and potentially the process 
of engulfment) enhanced protein expression, most notable CD40. Further investigation 
using in vivo tracing studies would be needed to determine if the acquisition of apoptotic 
cells induces the up-regulation of co-stimulatory molecules.  
Do Ly6C+ monocytes induce naïve CD8+ T cell proliferation? 
 As the monocytes that express co-stimulatory molecules (Signal 2) are also capable 
of presenting peptide onto surface MHC Class I (Signal 1), I next wanted to determine if 
monocytes can cross-present that cell-associated antigen to induce antigen-specific CD8+ T 
cell proliferation. To test this, CD45.2 splenic Ly6C+ monocytes and CD8α+ DCs were 
negatively enriched and FACS sorted to acquire a pure population. These were then co-
cultured with AOVA apoptotic thymocytes and enriched CFSE-labeled CD45.1 OT-1 T cells 
for 72 hours (Figure 3-11A). T cell enrichments were consistently over 90% pure (Figure 3-
11B). Proliferation was then determined by CFSE dilution. As expected, CD8α+ DCs 
induced robust proliferation, averaging 48.3% of T cells dividing (Figure 3-11C). However, 





Figure 3-10 A subpopulation of ex vivo Ly6C+ monocytes is positive for MHC Class I 
and co-stimulatory molecules. Negatively enriched Ly6C+ monocytes were plated in a 96-well 
flat-bottomed plate and cultured at 37ºC with either PBS or apoptotic thymocytes for 18 hours, and 
surface protein expression was assessed by flow cytometry. Negative controls included enriched 
monocytes cultured at 4ºC. Contour plot (left) identified MHC Class Ihi (blue), MHC Class Ilo (black) 
monocytes. Histogram plots represent expression of CD40, CD80 and MHC Class II of MHC Class Ihi 
and MHC Class Ilo cell populations in either PBS- or apoptotic cell-treated wells overlaid with 
monocytes cultured at 4ºC (grey dotted line). Plots are representative of three experiments, three 































Figure 3-11. Ly6C+ monocytes can present antigen to induce naïve CD8+ T cell 
proliferation. (A) Negatively enriched and FACS sorted CD45.2+ Ly6C+ monocytes and CD8α+ DCs 
were co-cultured with AOVA apoptotic thymocytes and CFSE-labeled CD45.1+ OT-1 T cells for 72 
hours. T cell proliferation was then determined by FACS analysis measuring CFSE dilution. (B) Dot 
plots showing purity of enriched CD3+CD8+ OT-1 T cells. (C) Histogram (top) and dot plots (bottom) 
showing percent proliferation of OT-1 T cells, plotted as bar graph (right). Data are representative of 











demonstrate the ability of monocytes to cross-prime in a more physiological setting, I 
employed an ex vivo strategy in which mice were treated intravenously with AOVA apoptotic 
thymocytes, and after an hour timepoint by which efferocytosis has occurred, monocytes 
were enriched by a negative-positive enrichment strategy. Enriched monocytes were then 
co-cultured with OT-1 T cells for 72 hours, as previous in vitro experiments. In these assays, 
cell-associated antigen acquired by monocytes in vivo is also capable of inducing naïve 
CD8+ T cell proliferation (8.9%). Proliferative differences between ex vivo and in vitro 
experiments could possibly be accounted for by differences in antigen acquisition, as in vitro 
efferocytosis assays had a greater proportion of uptake compared to in vivo studies, or 
could be due to culture-related upregulation of co-stimulatory molecules. The ability of Ly6C+ 
monocytes to induce proliferation of CD8+ T cells, combined with differential regulation of 
scavenger receptors relative to CD8α+ DCs, suggest Ly6C+ monocytes may uniquely 
promote CTL responses to particular pathogens. 
Discussion  
 In conclusion, I demonstrate that Ly6C+ monocytes have an intrinsic ability to acquire 
apoptotic cells (efferocytose), observed in both ex vivo and in vivo settings. In fact, within 
the spleen the total number of efferocytic monocytes is equivalent to efferocytic CD8α+ DCs. 
Preliminary data show that monocytes acquire apoptotic microvesicles (≤1uM) rather than 
whole cells or apoptotic bodies173. This combined with the observation that monocytes 
express transcript for CD14 and CD68 suggests efferocytosis occurs through a 
macropinocytosis-like mechanism involving tethering-induced engulfment; however 
preliminary data suggested CD14 was not required for splenic Ly6C+ monocyte 
efferocytosis46,55.  
Additionally, I saw efferocytosis by monocytes was not restricted to one mechanism 
of target cell apoptosis (UV-radiation), in that dexamethasone treated thymocytes were also 
engulfed by Ly6C+ monocytes. However, the efferocytosis efficiency of dexamethasone-
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treated thymocytes was slightly lower compared to UV-treated apoptotic cells. This could 
potentially be attributed to technique, in that free dexamethasone was inadvertently 
transferred into the mice potentially impacting monocyte function. More likely, the slight 
discrepancy is due to the mechanism of apoptosis that is induced, in that UV-radiation 
damages DNA, activating caspase -3/-8 (mitochondrial damage not occurring until later time 
points), whereas dexamethasone dysregulates mitochondria structure as an early response, 
prior to DNA fragmentation162,174.  Different mechanisms of programmed cell death within the 
undergoing apoptotic cell may involve discrete requirements for their recognition and 
removal by the monocyte.  
Ultimately, it would be beneficial in determining the mechanisms of acquisition by 
splenic Ly6C+ monocytes (such as the requirement for Scara1 and/or CD68), and the 
requirements for uptake of cells or associated microvesicles after inducing various types of 
cell death. This would have implications on monocyte endosome maturation/processing of 
antigen, as specific receptor-mediated endocytosis can dictate antigen trafficking to early 
versus late endosomes, and therefore dictate cross-presentation efficiency98,99. Furthermore, 
if ‘tissue resident’ Ly6C+ monocytes have non-redundant mechanisms of efferocytosis 
compared to other myeloid phagocytes, their niche role in the resolution of inflammation 
could be exploited by targeted therapeutics that promote that process.  
In this chapter, I also showed that Ly6C+ monocytes can cross-present cell-
associated antigen acquired from ingested apoptotic thymocytes and induce naïve CD8+ T 
cell proliferation. However, their efficiency was lower compared to CD8α+ DCs. One could 
hypothesize that monocytes and DCs utilize different mechanisms of cross-presentation. 
Batf3+ (CD8α+) DCs have been shown in many reports to undergo cytosolic cross-
presentation, argued to be more effective than the vacuolar theory97,154. Therefore, I would 
predict that monocytes undergo vacuolar cross-presentation. To this point, cross-
presentation by monocyte-derived DCs have been shown to be dependent on IRAP 
50 
 
(indicating vacuolar theory) whereas splenic CD8α+ DCs cross-presented in the absence of 
IRAP175. Additionally, preliminary data (n=1) of ours measuring splenic monocyte cross-
presentation deficient in TAP1 showed no hindrance in WT CD8+ T cell proliferation 
(compared to WT monocyte controls) (data not shown), thus use of the cytosolic cross-
presentation pathway is unlikely, supporting the hypothesis that monocytes present antigen 
through the vacuolar pathway. Alternatively, peptide-MHC: TCR kinetics could account for 
the lower efficiency of monocytes to cross-present and cross-prime naïve CD8+ T cells 
compared to CD8α+ DCs. Ly6C+ monocytes have a short half-life (~20 hours); however, 
TCR engagement required for naïve T cells is also approximately 20 hours33,176. This may 
implicate monocytes having a larger role at inducing memory, rather than naïve, T cell 
responses, which can become active from just 0.5-2 hours of TCR engagement.  
Our data suggests that even within the Ly6C+ monocyte population there may be a 
sub-population with distinct functional properties. That is, a subset that expresses higher 
levels of co-stimulatory molecules also present surface peptide:MHC Class I complexes. To 
this point, even within the CD8α+ DC population, one study shows CD8α+CD103+ DCs 
present cell-associated antigen better than CD8α+CD103- DCs, partially attributed to their 
ability to present antigen via the cytosolic pathway177. The notion of monocyte subsets 
beyond the classical/non-classical characterization is a developing interest for current 
researchers, providing a platform for new and exciting questions40. Such as, is the same 
subpopulation of monocytes that acquire antigen in the spleen observed in other tissues, 
and if so, is it responsible for trafficking antigen to draining lymph nodes? As the observed 
subgroup of Ly6C+ monocytes provide both Signal 1 and Signal 2 required by naïve T cells, 
do the same cells are also provide Signal 3 to drive T cell differentiation? Furthermore, if 
there are true sub-populations equipped to present antigen, is this ‘subset’ defined through 
development, or generated through environmental cues – a nature versus nurture 
phenomenon? Future experiments in vivo are crucial to address these questions, 
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particularly as I saw the process of enrichment and plating monocytes stimulated the 
upregulation of co-stimulatory molecules, and likely other molecules not limited to those 
involved in adhesion/trafficking. Beyond monocytes, studies assessing DCs in vitro show the 
induction of co-stimulatory molecules, such as CD70, more readily than in vivo, further 
indicating the need for parallel in vivo experiments178,179. However, as monocytes have a 
short half-life and are constantly being renewed, elegant tracing studies would be required 























THE ROLE OF TLR LIGATION FOR LY6C+ MONOCYTE EFFEROCYTOSIS, CROSS-
PRESENTATION AND CROSS-PRIMING2 
Introduction 
In the previous chapter I concluded that naïve Ly6C+ splenic monocytes can engulf 
apoptotic cells (efferocytose). Furthermore, a subpopulation of Ly6C+ monocytes load 
apoptotic cell-derived antigenic peptides onto MHC Class I molecules and express co-
stimulatory molecules that aid in the presentation to naive CD8+ T cells. In this chapter, I 
aimed to build upon our observations of naïve monocytes to now investigate the capacity of 
activated monocytes to efferocytose, cross-present and cross-prime cellular associated 
antigen from apoptotic cells. In these studies, monocytes are activated by use of agonists 
that represent conserved pathogen-associated molecule patterns (PAMPs).  
Additionally, in the last chapter I found that monocyte cross-presentation led to the 
activation and expansion of naïve CD8+ T cells. However, T cell proliferation is not 
equivalent to cytotoxic function. As a safe guard in preventing potentially harmful cytotoxic 
immune responses against self-antigens, an additional signal, beyond peptide:MHC:TCR 
(Signal 1) and co-stimulatory molecule (Signal 2) interactions, is required180. These 
additional signals are particularly important for cell-associated antigens, as homeostatic 
turnover of cells constantly supply potential apoptotic cell-derived antigens114,181. To 
distinguish foreign pathogenic material from self, innate immune cells express Toll-like 
receptors (TLRs) – surface and endosome bound signaling receptors - that bind conserved 
pathogenic patterns, or PAMPs115,130. TLRs have profound impact in shaping the generation 
of the adaptive immune responses by the activation of antigen-presenting cells (APCs), 
                                                          
2 With pu lisher’s per issio , portio s of this hapter have ee  odified fro  the origi al arti le Ly6C+ 
monocyte efferocytosis and cross-presentation of cell-asso iated a tige s . “R Larso , “M Atif, “L Gi i gs, 
SM Thomas, MG Prabagar, T Danhorn, SM Leach, PM Henson and CV Jakubzick. Cell Death and Differentiation 
(2016) 23, 997-1003. 
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upregulation of co-stimulatory molecules as well as consequent induction of cytokines and 
chemokines (Signal 3). As an example, Batf3+ DCs can induce T cell proliferation in 
response to cell-associated antigen, but only upon TLR3 ligation do they induce cytotoxic T 
lymphocyte (CTL) responses154. These findings held true using two models of cell-
associated antigens – the apoptotic AOVA thymocytes (as used in my studies), as well as 
apoptotic B16F10 metastatic melanocytes.  
In the current investigation, I sought to determine if TLRs contribute to monocyte 
efferocytosis, cross-presentation and cross-priming (generation of CTLs). A previous study 
showed that LPS-activated monocytes can induce CD8+ T cell proliferation, but their ability 
to cross-prime remains unknown36. Additionally, Ly6C+ monocytes express a range of TLRs, 
and therefore it is unclear how alternative agonists can influence monocyte antigen 
acquisition and presentation. 
I hypothesized and show that several TLR ligands enhance several key steps in the 
initiation of adaptive immunity– the engulfment of apoptotic cells expressing membrane 
bound antigen and the upregulation of co-stimulatory molecules. To our surprise, one TLR 
ligand, R848, selectively enhanced CD8+ T cell proliferation and their production of IFN , but 
did not promote the differentiation into CTLs, potentially due to its promiscuous binding 
outside of cognate TLR. This chapter depicts a dichotomy between monocyte and CD8α+ 
DC roles in immunity – where Ly6C+ monocyte responses to TLRs are most recognizable in 
initial antigen acquisition, and CD8α+ DC responses to TLR ligation more efficiently promote 
downstream cross-priming.  
Results 
Which TLRs are expressed in Ly6C+ monocytes? 
 To examine the role of TLRs in regulating Ly6C+ monocyte acquisition of apoptotic 
cells (efferocytosis), cross-presentation and cross-priming, I first set out to identify candidate 
TLRs to target for future experiments. To start, I measured TLR transcript expression in 
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naïve Ly6C+ monocytes. C57BL/6 (WT) splenic monocytes characterized as SSClo, 
CD11bhigh, Ly6Chigh were negatively enriched and FACS sorted to obtain pure populations, 
after which RNA was extracted for RNA sequencing. TLR mRNA expression levels were 
quantified by measuring transcript per million (TPM) count reads. Among the highest 
expressed were TLR2, TLR7 and TLR13, followed by TLR1, TLR4, TLR6, TLR8, TLR9 and 
TLR11 with moderate expression. TLR3 and TLR12 had little to no transcript expression 
(Figure 4-1A). In addition to transcript expression, TLR localization (surface- vs endosome-
bound) and downstream signaling through the adaptor protein myeloid differentiation 
primary response 88 (MyD88) were determinant factors for choosing our testing panel of 
TLRs (Figure 4-1B). For these reasons, I pursued TLR2, TLR4, TLR7, TLR9 and TLR13 for 
our studies. Traditional agonists were used - Pam3CSK4 [Pam3] (TLR2), LPS (TLR4), 
Resiquimod [R848] (TLR7/8), ODN 1668 [CpG] (TLR9) and ORN Sa19 [Sa19] (TLR13).  
Does TLR ligation enhance Ly6C+ monocyte efferocytosis?  
 First, I wanted to evaluate the possible contribution of TLR signaling to Ly6C+ 
monocyte efferocytosis - the first step for cross-presentation of cell-associated antigen. Ex 
vivo efferocytosis assays were performed on negatively enriched splenic Ly6C+ monocytes. 
Cells were plated onto a 96-well flat-bottomed plate for two hours to settle and adhere, after 
which CFSE-labeled apoptotic thymocytes were added to the cultures in combination with 
the TLR ligands Pam3, LPS, R848, CpG or Sa19. After one hour, apoptotic cell engulfment 
(efferocytosis) was determined by measuring the percentage of Ly6C+ monocytes that were 
CFSE(+). Monocytes treated with the TLR ligands Pam3, LPS, R848 and Sa19 displayed 
slight but significant enhancement in the percentage of cells that efferoctyosed (32.9%, 
28.1%, 31.3% and 33.5%, respectively), compared to those receiving apoptotic cells alone 




Figure 4-1. TLR transcript profile of naïve splenic Ly6C+ monocytes. (A) Splenic Ly6C+ 
monocytes were negatively enriched and pure populations were obtained by FACS sorting in 
triplicate. RNA was extracted for RNA sequencing. Graph displays TLR transcript per million (TPM) 
count reads (B) Depiction of TLRs and their ligands that were selected for future experiments. 
Targeted TLRs were chosen by transcript expression in (A), localization (surface- vs. endosome-
bound) and the downstream signaling adapter MyD88. TLRs (ligands) to be pursued include surface 









Figure 4-2 Multiple TLRs enhance splenic Ly6C+ monocyte, but not CD8α+ DC, 
efferocytosis in vitro. (A, C) Negatively enriched Ly6C+ monocytes and CD8α+ DCs were plated 
for two hours, followed by co-incubation with CFSE-labeled apoptotic thymocytes and TLR ligands for 
an hour. FACS analysis measuring percentage of (A) Ly6C+ monocytes and (C) CD8α+ DCs that 
were CFSE+ are plotted in column graphs. (B) Monocytes from (A.) were treated with three doses of 
the following TLR ligands: Pam3 (10pg, 100pg, 1ng), LPS (10ng, 100ng, 1µg), R848 (30ng, 300ng, 
3µg), CpG (10ng, 100ng, 1µg) and Sa19 (10ng, 100ng, 1µg). Dilution 1 represents the highest dose 



















were CFSE(+). Additionally, I evaluated multiple doses of each TLR ligand to determine if 
increased concentration had an impact on monocyte acquisition of apoptotic cells. I was 
particularly interested if a higher dose of CpG would increase efferocytosis, as in previous 
experiments it was the only ligand to have no enhanced effects. Increased CpG and LPS 
doses trended towards decreased monocyte efferocytosis; however, there was no statistical 
dose response with any of the ligands tested (Figure 4-2B). The decrease of efferocytosis 
in the presence of higher doses of CpG and LPS could be due to inadvertent TLR-induced 
apoptosis of the monocytes182. Our lack of dose response is supported by previous reports 
that show TLR9 signaling does not benefit from increased local concentration of ligand117. 
Alternatively, it has been reported that TLR9-ligand interactions bind in a pH dependent 
manner, and as eluded to in Chapter III, monocytes have a near-neutral endosomal pH and 
may therefore attenuate optimal ligand binding183,184. In contrast to monocytes, CD8α+ DCs 
treated in vitro (Figure 4-2C) maintained their inherent ability to efferocytose, but was not 
augmented by the any of the TLRs tested.  
I next performed assays to determine if enhanced TLR-mediated efferocytosis 
occurred in vivo. WT mice were intravenously treated with CFSE-labeled apoptotic 
thymocytes and TLR ligands, and after an hour time point, spleens were harvested for 
examination of splenic monocytes that were CFSE positive. In vivo experiments 
paralleled the in vitro results, in that of the TLRs targeted, TLR4 and TLR7 ligation 
significantly enhanced the percentage of CFSE(+) monocytes two-fold (20.8% and 21.5%, 
respectively), compared to those receiving apoptotic cells alone (10.8%) (Figure 4-3A). 
Mirroring percentages, there was a shift in the MFI expression of CFSE upon LPS (blue) and 
R848 (red) treatment compared to those receiving either CpG (green), PBS (black) or PBS 
receiving no apoptotic cells (grey, dotted), suggesting TLR ligation promotes more ingestion 
of apoptotic cell material within individual cells. As seen in the in vitro studies, CD8α+ DCs 





Figure 4-3 Multiple TLRs enhance splenic Ly6C+ monocyte, but not CD8α+ DC, 
efferocytosis in vivo. WT mice were intravenously injected with CFSE-labeled apoptotic 
thymocytes and TLR ligands. After one hour, spleens were harvested and the percentage of Ly6C+ 
monocytes (A) and CD8α+ DCs (B) that were CFSE+ were quantified. (C, D) Histogram graph 
represents CFSE expression, indicating apoptotic cell engulfment, for Ly6C+ monocytes and CD8α+ 












percentages and CFSE MFI expression (Figure 4-3B). Of interest, TLR-treated monocytes 
efferocytose proportionally to CD8α+ DCs (~20-25%), highlighting their importance in host 
defense upon inflammatory insult. Overall, this shows that Ly6C+ monocytes, but not CD8α+ 
DCs, respond to pathogenic exposure (TLR ligation) to enhance their functional property of 
antigen acquisition.  
Is enhanced efferocytosis dependent on specific TLR ligation and signaling through 
MyD88?    
 I next wanted to confirm TLR ligation is due to direct ligand-receptor binding on the 
monocyte. I focused on TLR7 as R848 displayed enhanced efferocytosis in both the in vivo 
and in vitro experiments, and unlike TLR4, TLR7 only signals through MyD88. WT and 
TLR7-/- mice were intravenously treated with CFSE-labeled apoptotic thymocytes and either 
PBS, LPS or R848 for one hour. As previously observed in WT mice, LPS and R848 
enhanced the proportion of monocytes that were CFSE(+). In TLR7-/- mice, LPS but not 
R848 enhanced efferocytosis (Figure 4-4A). To further illustrate the necessity of TLR 
signaling for enhanced efferocytosis, similar experiments were performed in mice deficient 
of MyD88, the downstream signaling adaptor of TLR7. MyD88-/- mice was analogous to the 
TLR7-/- mice, in which R848 treatment in the knock-out monocytes displayed no enhanced 
efferocytosis compared to WT (Figure 4-4B). R848 is a dual TLR7/8 agonist, and while 
TLR8 is considered non-functional in mice, I wanted to further prove that TLR7 ligation can 
enhance efferocytosis127,185. Therefore, I utilized TLR7 specific ligands – Imiquimod (R837) 
and CL264 – to measure in vitro monocyte efferocytosis. Enriched monocytes were plated 
and co-cultured with CFSE-labeled apoptotic cells with either PBS, CL264, R837 or R848 
and analysis performed after one hour. In these experiments, each TLR7 ligand significantly 







Figure 4-4 TLR7-mediated efferocytosis is dependent on specific TLR signaling. (A, B) 
WT, TLR7-/- and MyD88-/- mice were intravenously treated with CFSE-labeled apoptotic thymocytes 
and PBS, LPS or R848 for one hour. Efferocytosis was measured as the percentage of CFSE+Ly6C+ 
monocytes. Graphs displays cumulative data of (A) three independent experiments with 2-3 mice per 
group, and (B) two independent experiments with 1-2 mice per group. (C.) WT monocytes were 
negatively enriched and plated for two hours. CFSE-labeled apoptotic thymocytes with either PBS or 
the TLR7 ligands CL264, R837 or R848 were co-cultured for one hour and efferocytosis assessed. 
Graph represents data from three independent experiments with 3-4 wells per group. (D) Structures 











the data show that specific TLR ligation and signaling on monocytes enhance the proportion 
of monocytes that acquire apoptotic cells.  
Do TLR ligands enhance Ly6C+ monocyte induction of naïve CD8+ T cell proliferation?  
As multiple TLR agonists promote monocyte efferocytosis in a receptor dependent 
manner, I next wanted to determine how TLR activation on monocytes might regulate 
downstream processing of acquired antigen. As an indirect measure of antigen processing 
and cross-presentation, I first assessed T cell activation and proliferation induced by TLR-
treated Ly6C+ monocytes in vitro. I anticipated one of two possible outcomes, that either 1) 
TLRs residing in endosomal compartments (TLR7, TLR9 and TLR13), or 2) TLRs that are 
highly expressed on the transcript level (TLR2, TLR7 and TLR13) would enhance antigen-
specific CD8+ T cell proliferation. To test if either of these predictions are true, congenic 
CD45.2+ Ly6C+ monocytes were negatively enriched and FACS sorted to obtain a pure 
population. They were then co-cultured with AOVA apoptotic thymocytes, TLR ligands and 
CFSE-labeled CD45.1+ OT-1 T cells. As an initial assessment, T cell activation by 
glycoprotein CD69 expression was measured after 24 hours of co-culture (Figure 4-5A)186.  
To our surprise, R848 was the only TLR ligand to significantly induce the 
upregulation of CD69 expression on CD8+ T cells. Next, I assessed T cell proliferation by 
setting up a similar experiment, but instead of CD69 expression, measured CFSE dilution of 
the CD8+ T cells at 72 hours. As seen in previous studies (Chapter III), Ly6C+ monocytes 
co-cultured with AOVA apoptotic cells induced 23.8% OT-1 T cell proliferation. Adding LPS, 
CpG or Sa19 had no effect on downstream T cell proliferative responses (23.3%, 23.5% and 
24.9%, respectively) (Figure 4-5B-C). Pam3 treated wells had a slight enhancement 
compared to PBS control, at 28.4% proliferation, but most striking was R848 enhancing 
proliferation two-fold, at 48.7%. All proliferating cells were positive for the activation marker 





Figure 4-5 R848 enhances the activation and proliferation of naïve CD8+ T cell by 
Ly6C+ monocytes in vitro. Sorted Ly6C+ monocytes from CD45.2+ congenic mice were plated in 
a 96-well round bottom plate and co-cultured with AOVA apoptotic thymocytes, enriched CD45.1+ 
CFSE-labeled OT-1 T cells and PBS ± TLR ligands. (A) After 24 hours, mean fluorescence of CD69 
expression on CD45.1+CD8+ T cells was quantified. Graph depicts two independent experiments with 
2-4 wells per group. (B-D) After 72 hours proliferation by CFSE dilution was assessed. Dot plots and 
histogram plots (B) measure percent proliferation, quantified in (C). The total number of proliferative T 
cells within each well (D), and the proliferation index (E) was quantified. Graphs represent 















and the size of each peak on day 3, in which R848 induced 4-5 strong rounds, compared to 
~3 rounds induced by any other experimental conditions (Figure 4-5B). Measuring total 
number of OT-1 T cells in each well mirrored percent proliferation in which Pam3 enhanced 
the total number of CD8+ T cells compared to PBS control, but R848 was the most robust 
(Figure 4-5D). Lastly, the proliferation index was calculated to determine the number of cells 
undergoing multiple divisions (http://docs.flowjo.com/vx/experiment-based-
platforms/proliferation/) and the same trend was observed, in which R848 treated 
monocytes had a significant enhancement compared to other treatment groups (Figure 4-
5E). Overall, the data suggest that each of our original hypotheses were wrong, in that 
relative TLR transcript expression and/or TLR localization do not dictate the efficiency of 
monocytes to cross-present and potentially cross-prime. Rather, the TLR7 agonist, R848, 
enhanced monocyte-mediated antigen presentation and activation of CD8+ T cells. 
Interestingly, monocytes treated with R848 have comparable ability to induce T cell 
proliferation in vitro compared to inactivated CD8α+ DCs (Figure 3-11).  
As an additional measure of CD8+ T cell activation, I assessed IFN  production by 
the proliferating CD8+ T cells. For this, CD45+ Ly6C+ monocytes were enriched and sorted, 
then co-cultured with AOVA apoptotic thymocytes, CFSE-labeled apoptotic cells and our 
panel of TLR ligands. After five days, the cultures were re-stimulated with OVA257-264 
(SIINFEKL) peptide in the presence of Brefeldin A (BFA) and IL-2 for five hours. Cells were 
then fixed and permeabilized for intracellular IFN  staining. In these experiments, IFN  
production did not occur until the 6th division (Figure 4-6A). Treating wells with Pam3 and 
Sa19 had a significant increase in IFN  production (16.4% and 18.γ%, respectively) 
compared to wells receiving no TLR stimulus, LPS or CpG (1.8%, 0.2% and 2.3%, 
respectively). R848 treatments induced the most robust IFN  production, in which β9.1% of 






Figure 4.6. R848 treated Ly6C+ monocytes induce robust IFNγ production by CD8+ T 
cells in vitro. (A) CD45.2+ Ly6C+ monocytes were enriched and FACS sorted to obtain pure 
populations. They were then co-cultured with AOVA apoptotic thymocytes and enriched CFSE-
labeled OT-1 T cells with our panel of TLR ligands. After five days, 5^4 enriched CD45.2+ MHC Class 
II+ splenocytes were added to the cultures, with OVA257-264 peptide, IL-2 and BFA for five hours. Cells 
were then fixed, permeabilized and stained for intracellular IFN . Dot plots representative of IFN  
stain of dividing OT-1 T cells. Graph (below) displays percentages of IFN + cells from two 
independent experiments, with 3 wells per group. (B) Co-cultures systems were set up including 
enriched and FACS sorted CD45.2+ Ly6C+ monocytes, AOVA apoptotic thymocytes, CFSE-labeled 
OT-1 T cells and TLR ligands. After three days, supernatant was removed for ELISA assays. IFN  
per well was calculated from standard curve dilution. Graph represents cumulative data from five 
experiments, with 3-5 wells per group. (C) WT mice were intravenously treated with either PBS, 
CFSE-labeled apoptotic cells ± LPS or R848. After an hour, splenic monocytes were enriched and 
FACS sorted for RNA sequencing, in triplicate. Graph displays transcript per million (TPM) count 









enzyme-linked immunosorbent assay (ELISA) from our co-culture systems on day 3. 
Secreted IFN  paralleled intracellular IFN  stain, in that Pamγ and Sa19 treatments trended 
toward an increase production compared to PBS, LPS or CpG treatments (Figure 4-6B). As 
before, R848 induced the most robust secretion, significantly greater than every other 
experimental group. I can conclude the IFN  released is from the activated OT-1 T cells and 
not from the Ly6C+ monocytes, as efferocytic Ly6C+ monocytes do not upregulate IFN  
transcript expression when treated in vivo with apoptotic cells and R848 (Figure 4-6C). 
Collectively, this data shows that in vitro R848 treatment significantly enhances the 
activation of CD8+ T cells.  
Next, I wanted to confirm that R848-mediated T cell proliferation was due to 
enhanced cross-presentation/cross-priming by the Ly6C+ monocytes, rather than R848 
acting on other cells in the co-culture system. First, I assessed the potential of the OVA-
expressing apoptotic thymocytes to induce CD8+ T cell activation by performing proliferation 
assays in the absence of Ly6C+ monocytes. In this setting, the only source of antigen T cells 
are exposed to is from the constitutive OVA expressing apoptotic thymocytes. Co-cultures of 
AOVA apoptotic thymocytes with TLR ligands and CFSE-labeled OT-1 T cells were 
assessed after 72 hours for proliferation. Wells containing monocytes ± R848 treatment 
were included as positive comparisons. In the absence of monocytes there was 
minimal proliferation (Figure 4-7A). Furthermore, in the absence of monocytes, R848 
treated AOVA apoptotic thymocytes did not significantly enhance the number of CD8+ T 
cells compared PBS control. Next, I wanted to examine the potential of R848 to act directly 
on the CD8+ T cells. For this, enriched CFSE-labeled OT-1 T cells and TLR ligands were 
cultured on pre-coated anti-CD3 plates for the assessment of T cell proliferation after 72 
hours. In these experiments, TLR ligation had no significant impact on enhancing CD8+ T 
cell proliferation (Figure 4-7B). Therefore, I can conclude that R848 acts directly on Ly6C+ 






Figure 4-7 R848 does not signal on antigen-expressing thymocytes or CD8+ T cells to 
enhance T cell proliferation. (A) AOVA apoptotic thymocytes were co-cultured with CFSE-
labeled OT-1 T cells and TLR ligands for 72 hours, after which T cell proliferation was assessed by 
FACS analysis. Positive controls included wells with FACS sorted Ly6C+ monocytes ± R848. Graph 
represents data from three independent experiments with three wells per group. (B) 96-well flat-
bottomed plates were coated with anti-mouse CD3 antibody overnight. The following day, plates were 
washed and enriched CFSE-labeled OT-1 T cells and TLR ligands were added to the wells. After 72 
hours, the number of proliferative T cells were quantified by FACS analysis. Graph represents two 














TLR ligation can induce apoptosis, therefore, I next wanted to determine if TLR 
ligation, particularly R848, either promotes or attenuates cell viability, which could impact  
downstream T cell proliferation efficiency188–190. To assess how TLR ligation impacts Ly6C+ 
monocyte survival, negatively enriched monocytes were co-cultured with apoptotic 
thymocytes, TLR ligands and a set number of 3µM yellow-green (YG) latex beads. The 
beads were added to obtain an accurate cell count of monocytes within each well by flow  
cytometry. Using 3µM sized beads ensured they would not be phagocytosed, as I previously 
showed monocytes acquire material ≤1µM. Monocytes incubated for 18 hours at 4ºC were 
used as a control. After 18 hours, I first evaluated general monocyte morphology upon TLR 
ligation by gating cells on forward scatter (FSC), proportional to cellular size, and side 
scatter (SSC), indicating cell granularity. While there were no obvious differences in 
monocyte granularity, there were differences in the proportions of monocytes that 
maintained their approximate size (Figure 4-8A). A smaller percentage of monocytes 
retained their size when no TLR treatment was given. Additionally, LPS increased the 
proportion of monocytes that had reduced size. Pam3, followed by R848, CpG and Sa19 
had the largest percentage of cells that retained their size, respectively. Next, Ilooked at 
DAPI stain as an indicator of cell death and counted to total number of live monocytes, 
calculated from the known number of beads. DAPI is a membrane impermeant dye that 
intercalates with DNA and RNA, therefore, cells that are DAPI(-) have a continuous 
membrane and considered viable. To our surprise, there were no significant differences in 
the total number of DAPI(-) monocytes within each well in the presence of absence of TLR 
ligands (Figure 4-8B). Therefore, the cell shrinkage observed does not correlate to 
membrane permeability, at least at the 18-hour timepoint, and in our experiments the same 
number of monocytes within each well could be presenting antigen to induce T cell 
proliferation. I next wanted to determine if TLR ligation impacts CD8+ T cell survival. In these 





Figure 4-8 TLR ligation does not impact Ly6C+ monocyte or CD8+ T cell viability in 
vitro. (A, B) Enriched monocytes were co-cultured with apoptotic thymocytes and PBS or TLR 
ligands for 18 hours in a 96-well flat bottom plate. 3^4 3µM YG-latex beads were added to each well, 
and then viability was assessed by flow cytometry. (A) Dot plots represent Ly6C+ monocytes gated by 
FSC and SSC. Monocytes incubated for 18 hours at 4ºC were used as a control. (B) Graph 
represents cumulative data quantifying total number of live cells by calculating the number of DAPI(-) 
Ly6C+ monocytes to the set number of beads within each well. Data are from four independent 
experiments with three wells/group. (C, D) Enriched CFSE-labeled CD45.1+ OT-1 T cells were co-
cultured with FACS sorted CD45.2+ Ly6C+ monocytes, AOVA apoptotic thymocytes and PBS or TLR 
ligands. After 5 days, T cell viable was determined as Ghost Dye Red 780 Stain (-). Bar graph (C) 







TLR ligands and enriched CFSE-labeled CD45.1+ OT-1 T cells. On day 5, T cell viability was 
assessed by Ghost Dye Red 780 expression. Ghost Dye Red 780 binds free amines in cells  
with compromised membranes, similar to DAPI. In this experiment, there was a trend of 
Pam3, R848 and Sa19 ligands promoting T cell survival compared to the other treatment 
groups, but was not significant (Figure 4-8 C, D). Therefore, I concluded that R848 had no 
effect on co-culture cell survival, and hypothesized that R848 ligation promotes naïve CD8+  
T cell proliferation by enhancing either Signal 1, Signal 2, or Signal 3 in cross-
presentation/cross-priming responses.  
Does R848 selectively enhance Ly6C+ monocyte cross-presentation (Signal 1)? 
 With our initial hypotheses that TLR transcript expression and/or endosome 
localization would promote monocyte induced activation and proliferation of CD8+ T cells, I 
was surprised to find that selectively R848 had enhanced effects. I ruled out the possibility 
of TLR induced apoptosis of either Ly6C+ monocytes are CD8+ T cells, as well as antigen 
acquisition (efferocytosis) regulating T cell proliferation. This is in line with previous literature 
showing amount of antigen acquired does not correlate to cross-presentation efficiency191. I 
next wanted to address if R848 enhances the physical loading of peptide onto MHC Class I 
molecules. First, I looked indirectly at antigen processing and presentation by measuring 
endosome acidification. I assessed the potential of endosome acidification by measuring 
transcript levels of v-ATPase subunits. For this, WT mice were intravenously treated with 
either PBS, CFSE-labeled apoptotic thymocytes ± LPS or R848. After one hour, spleens 
were harvested for monocyte enrichments and FACS sorted to obtain pure populations. 
RNA sequencing was performed on naïve or CFSE+ monocyte populations. Monocytes that 
were treated with apoptotic thymocytes had minimal alterations in transcript expression of v-
ATPase subunits (Figure 4-9A). Monocytes treated with apoptotic thymocytes and LPS had 
a reversal in gene expression compared to naïve monocytes, in that half of the subunit 




Figure 4.9 R848 treatment altered v-ATPase and NADPH oxidase RNA transcript in 
Ly6C+ monocytes. WT mice were treated with either PBS, CFSE-labeled apoptotic thymocytes ± 
LPS or R848. After one hour, spleens were harvested, negatively enriched and either naïve or CFSE+ 
Ly6C+ monocytes were FACS sorted in triplicate. RNA was extracted for RNA sequencing. Heat 
maps were generated by the web-based Morpheus tool and are displayed as row scaled data where 
blue and red indicate relative low and high transcript expression, respectively. Lowest and highest 
transcript per million count reads for each gene across samples are listed in parenthesis on right. 
Heat maps display selected transcript for subunits associated with the (A) v-ATPase or the (B) 















monocytes treated with apoptotic thymocytes and R848 had a reduction or maintained 
transcript expression of nearly every subunit. This was promising data that suggested R848  
may enhance cross-presentation by reducing endosome acidification. Next, I similarly 
measured transcript expression of NADPH oxidase subunits. As with measuring v-ATPase 
subunits, the acquisition of apoptotic thymocytes did not alter the transcriptional profile of 
NADPH oxidase subunits (Figure 4-9B). LPS treatment led to a general downregulation of  
most subunits, whereas R848 induced an increase in the subunits Cybb (NOX2/gp91phox), 
Ncf1 (p47phox) and Ncf4 (p40phox). Together, this transcript profile with R848 treated 
monocytes suggests that TLR7 ligation promotes the neutralization of endosomes, which 
may contribute to enhanced CD8+ T cell proliferation responses. 
To translate transcript data to functional responses, relative pH was determined by 
using pHrodo dyes which increase in fluorescence as the surrounding environment acidifies. 
Enriched monocytes were plated with pHrodo-SE labeled YG 0.1µM carboxylated beads 
and either LPS or R848 for one hour. Although carboxylated latex beads are not digested, 
they mimic surface charges of apoptotic cells and are acquired through similar mechanisms, 
and were therefore used as a surrogate for apoptotic cells163. Neutrophils were included as a 
positive control. By flow cytometry, relative endosome pH of monocytes that had digested 
beads was determined by measuring the MFI of the PE channel (pHrodo). In these 
experiments, bead(+) monocytes treated with either PBS (grey shaded line), LPS (blue line) 
or R848 (red line) did not noticeable acidify their endosomes, as evident by the minimal shift 
of pHrodo fluorescence compared to bead(-) monocytes (dashed line) (Figure 4-10A). 
Lastly, I wanted to evaluate the effects of the NADPH oxidase on cross-presentation, as 
CD8α+ DCs require sustained ROS generation, independent of v-ATPase activity95,164. I 
tested the necessity of the p47phox cytosolic subunit of the NADPH oxidase in R848-
mediated cross-presentation, as Ncf1 has been implicated in cross-presentation of soluble 





Figure 4.10 R848 does not alter Ly6C+ monocyte endosome activity as a mechanism 
for enhanced T cell activation. (A) Enriched monocytes were plated in a 96-well flat-bottomed 
plate for two hours. 0.1µM YG-carboxylated beads labeled with pHrodo dye were added with either 
PBS, LPS or R848 for one hour. Relative endosome acidity was measured by mean fluorescence 
intensity (MFI) of the PE channel of bead+ cells by FACS analysis. Histogram represents monocytes 
that are bead(-) (dashed line) and bead(+) monocytes treated with PBS (grey shaded line), LPS (blue 
line) and R848 (red line). Neutrophils were used as a positive control (black dotted line). Data are 
from two independent experiments with 4 wells/group. (B) CD45.2+ WT or Ncf1-/- monocytes were 
enriched and co-cultured with AOVA apoptotic thymocytes, enriched CD45.1+ CFSE-labeled OT-1 T 
cells and either PBS, LPS or R848. After 72 hours, total number of proliferative CD8+ T cells were 














labeled OT-1 T cells, AOVA apoptotic cells and either PBS, LPS or R848. After three days, 
the total number of proliferated CD8+ T cells within each well were quantified. 
Unsurprisingly, induction of T cell proliferation was reduced in the absence of Ncf1; 
however, when comparing Ncf1-/- monocytes from PBS and R848 treatments, R848 groups 
still displayed a significant enhancement (Figure 3-10B). This suggests that endosome  
maturation contributes to cross-presentation, but R848 does not alter these properties when 
presenting antigen to induce CD8+ T cell proliferation.  Ultimately, antigen processing within 
the endosome leads to the generation of productive peptides that are presented onto MHC 
Class I molecules on the surface of the antigen-presenting cells. I measured surface peptide 
expression on Ly6C+ monocytes in the presence of TLR ligands to further determine if R848 
enhances monocyte cross-presentation. Negatively enriched monocytes were plated with 
AOVA apoptotic thymocytes and our panel of TLR ligands. After 18 hours, I assessed 
peptide presentation on DAPI(-) monocytes by expression of 25-D1.16 stain. 25-D1.16 
antibody selectively recognizes the SIINFEKL peptide from ovalbumin that is complexed to 
MHC Class I. Sensitivity for this antibody is particularly low, so peptide expression was 
measured on monocytes expressing high levels of MHC Class I (Figure 4-11A top panels). 
As expected, peptide (SIINFEKL):MHC Class I complex expression was greater on MHC 
Class Ihi monocytes (Figure 4-11A, bottom panels). Of the MHC Class Ihi monocytes, Sa19 
treatment had a significant increase in SIINFEKL expression, and Pam3 treatment trended 
toward an increase, albeit the differences were small (Figure 4-11B). However, R848 had 
no significant enhancement of peptide presentation. These data combined show that R848 
treatment of monocytes does not regulate antigen processing or promote cross-presentation 








Figure 4.11 R848 ligation does not enhance Ly6C+ monocyte SIINFEKL: MHC Class I 
complex expression in vitro. Negatively enriched Ly6C+ monocytes were plated in a 96-well flat-
bottom plate with AOVA apoptotic thymocytes and TLR ligands. After 18 hours, surface 
SIINFEKL:MHC Class I expression was measured by mean fluorescence intensity (MFI) of 25-D1.16 
stain. (A) Dot plots (top panels) show sub-populations of monocytes that are MHC Class Ilo (black) 
and MHC Class Ihi (blue) for each TLR ligand treatment. Histograms (bottom panels) show overlaid 
MHC Class I subpopulations of monocytes, evaluating SIINFEKL:MHC Class I stain. (B) Graph 
shows quantification of 25-D1.16 MFI stain for each TLR ligand treatment. Data are from 3 








Does R848 selectively enhance co-stimulatory molecule expression on Ly6C+ 
monocytes (Signal 2)? 
The previous section showed that T cell proliferation in response to R848 treatment 
is not due to enhanced Ly6C+ monocyte cross-presentation (Signal 1). I next wanted to 
determine if co-stimulatory molecule expression (Signal 2) was selectively enhanced on  
monocytes treated with R848. For this, enriched Ly6C+ monocytes were plated and cultured 
with apoptotic thymocytes and our panel of TLR ligands. After 18 hours, surface 
protein expression of the co-stimulatory molecules CD40, CD80 and CD86 were measured, 
in addition to MHC Class I, on DAPI(-) monocytes. As before, there was a population of 
Ly6C+ monocytes that were high expressers of MHC Class I (blue), observed with each TLR 
ligand. However, multiple ligands - Pam3, R848 and Sa19 - enhanced the proportion of 
monocytes that were MHC Class Ihi compared to those receiving no TLR stimulus, or with 
CpG (Figure 4-12). LPS interestingly had a reduction in the percentage of higher expressing 
cells (Figure 4-12). When measuring CD40, CD80 and CD86, I saw the same trend, in that 
there was a population that had higher protein expression, and the percentage of DAPI(-) 
Ly6C+ monocytes that fell in the positive gate was increased upon Pam3, R848 and Sa19 
treatment. This could potentially be explained by Ly6C+ monocytes expressing the highest 
transcript levels for their corresponding TLRs (TLR2, TLR7 and TLR13, respectively), 
although while transcript expression is indicative, does not equate to protein receptor 
expression. Furthermore, when tracking the high co-stimulatory molecule expressing 
monocytes, the majority of CD40hi (green), CD80hi (red) and CD86hi (purple) also had higher 
expression of MHC Class I, most apparent with Pam3, R848 and Sa19 treatment (Figure 4-
12, bottom panels). This shows that these cells are all part of the same monocyte sub-
population.  
Further evaluating co-stimulatory molecule expression upon TLR ligation, the MFIs of 




Figure 4.12 TLR ligands Pam3, R848 and Sa19 enhance a sub-population of Ly6C+ 
monocytes that express higher levels of co-stimulatory molecules and MHC Class I. 
Negatively enriched Ly6C+ monocytes were co-cultured with apoptotic thymocytes and TLR ligands in 
a 96-well flat-bottomed plate for 18 hours. After, surface protein expression of the co-stimulatory 
molecules and MHC Class I was assessed by flow cytometry. Dot plots represent populations of 
monocytes that express high levels of MHC Class I (blue), CD40 (green), CD80 (red) and CD86 
(purple) and monocytes that express low levels for each molecule (black) upon each TLR ligand 
treatment. Histogram plots overlay each monocyte population with high co-stimulatory molecule 
expression measuring MHC Class I expression. Dotted line represents total monocyte population. 






monocyte population. Paralleling representative percentages previously observed (Figure 4-
12), the MFI of MHC Class I was enhanced when monocytes were treated with Pam3, R848 
or Sa19 (Figure 4-13A). CD40 expression was significantly enhanced with Pam3 and R848 
treatment (Figure 4-13B) and CD80 expression was enhanced with Pam3 and Sa19 
treatment (Figure 4-13C). CD86 expression had a slight, insignificant increase with Pam3, 
R848 and Sa19 treatments, likely due to variability between experiments (Figure 4-13D). 
Ultimately, characterization of surface co-stimulatory molecule expression suggests that 
enhanced co-stimulatory interactions between Ly6C+ monocytes and CD8+ T cells is not the 
mechanism for R848-mediated CD8+ T cell proliferation.  
Lastly, while R848 did not selectively enhance co-stimulatory molecule expression 
on Ly6C+ monocytes, I wanted to determine the functional role of co-stimulation in R848-
mediated T cell proliferation. For this, enriched Ly6C+ monocytes were co-cultured with 
AOVA apoptotic thymocytes, CFSE-labeled OT-1 T cells and either PBS or R848. 
Additionally, I added co-stimulatory molecule activating or blocking antibodies to our co-
cultures. After three days, T cell proliferation was assessed. First, I assessed the role of 
CD80 and CD86 on monocytes by stimulating CD28193. When CD28:CD80/86 interactions 
were enhanced, there was a slight reduction in total proliferating OT-1 T cells (Figure 4-
14A). However, R848 still significantly enhanced T cell proliferation, even in the presence of 
anti-mouse CD28. Next, I looked at the co-stimulatory molecule CD40 by blocking it directly 
on the monocyte. Treating wells with anti-mouse CD40 slightly enhanced T cell proliferative 
responses, in both the presence and absence of R848 (Figure 4-14B). The enhanced 
proliferation is likely due to enhanced activation of the monocytes, as the 1C10 clone for 
anti-mouse CD40 had been reported to stimulate B cell proliferation, while blocking CD40-
CD40L interactions194. Because enhancing co-stimulation by engaging CD28 on the T cells, 








Figure 4.13 Multiple TLR ligands enhance MHC Class I and co-stimulatory molecule 
expression on viable Ly6C+ monocytes in vitro. (A-D) Negatively enriched Ly6C+ monocytes 
were co-cultured with apoptotic thymocytes and TLR ligands in a 96-well flat-bottomed plate for 18 
hours. After, mean fluorescence intensity (MFI) was calculated on DAPI(-) monocytes by flow 
cytometry for (A) MHC Class I and the co-stimulatory molecules (B) CD40, (C) CD80 and (D) CD86. 






Figure 4.14 Blocking CD40-, CD80-, CD86-interactions does not attenuate R848-
mediated Ly6C+ monocyte induction of T cell proliferation in vitro. (A-C) CD45.2+ Ly6C+ 
monocytes were sorted and co-cultured with AOVA apoptotic thymocytes, CFSE-labeled OT-1 T cells 
± anti-mouse CD28 or CD40, and either PBS or R848. After 72 hours, the total number of proliferative 
T cells was quantified by flow cytometry. (A) Experiments measuring T cell proliferation in response to 
anti- mouse CD28 were performed twice, with three wells/group. (B) T cell proliferation in response to 



























on T cell proliferation, this suggests that co-stimulation by Ly6C+ monocytes plays a minor, 
unselective role in R848-mediated T cell proliferation. 
Does R848 selectively enhance the release of cytokines that drive T cell cytotoxic 
effector functions (Signal 3)? 
It appears that T cell proliferative responses driven by R848 are not attributed to the 
monocyte providing either enhanced cross-presentation (Signal 1) or enhanced co-  
stimulation (Signal 2). Given this, I predicted that R848 enhances T cell activation and 
possibly cross-priming through the production of a secreted mediator (Signal 3) that drives 
CD8+ T cell differentiation into a cytotoxic T lymphocyte (CTL). To initially this hypothesis, 
RNA transcript values of candidate Signal 3 cytokines – IL-6, IL-1βα, IL-1β , IL-15, IL-18 
and IL-27 were measured. For this, mice were treated intravenously with PBS or CFSE-
labeled apoptotic thymocytes with or without R848. After an hour, spleens were harvested 
for monocytes for RNA sequencing. As shown in Figure 4-15A, R848 stimulated the 
transcription of selected cytokines, as shown by measuring transcript per million (TPM) for 
monocyte enrichment and FACS sorting of naïve and antigen acquiring (CFSE+) count 
reads. It was next important to determine if this upregulated transcript expression correlated 
to actual protein production. For this, I compared R848 to Pam3 treatments, as both 
upregulated co-stimulatory molecules, and both were capable of activating CD8+ T cells, 
evidenced by IFN  production. Naïve FACS sorted splenic monocytes were co-cultured with 
TLR ligands for 18 hours. After, the supernatants were used to assay for a panel of 
cytokines by using a membrane-based cytokine array. In this experiment, the cytokines 
upregulated in the transcript data with R848 treatment were not visible. This was likely due 
to low sensitivity of the assay, rather than biology, and therefore largely inconclusive. 
However, there was increased production of two soluble factors – chemokine ligand 5 
(CCL5) and interleukin 1 receptor antagonist (IL-1ra) – by R848 treated monocytes 





Figure 4.15 R848-treated Ly6C+ monocytes upregulate RNA transcript expression and 
selectively secrete soluble mediators that may be involved in CD8+ T cell 
differentiation. (A) WT mice were treated with either PBS, CFSE-labeled apoptotic cells ± R848. 
After an hour, splenic monocytes were enriched and FACS sorted for RNA sequencing, in triplicate. 
Graphs display transcript per million (TPM) count reads for the cytokines IL-6, IL-1βα, IL-1β , IL-15, 
IL-18 and IL-27. (B) Ly6C+ monocytes were enriched and FACS sorted to obtain pure populations. 
Cells were plated with either PBS, Pam3 or R848 for 18 hours. The supernatant was then collected to 
















I followed up on CCL5 as a potential mediator that drives T cell proliferation, as it is a 
chemoattractant (Signal 0) for monocytes and memory T cells, and may encourage cross-  
talk in our in vitro studies195. To test if soluble CCL5 contributes to T cell proliferative 
responses, I performed in vitro T cell proliferation assays in the presence of recombinant  
CCL5. Naïve FACS sorted Ly6C+ monocytes were co-cultured with AOVA apoptotic 
thymocytes, CFSE-labeled OT-1 T cells, TLR ligands and rCCL5 for 72 hours. After, the 
total number of proliferative T cells were quantified. In these experiments, R848 significantly 
upregulated the total number of T cells, as previously observed; however, adding 
recombinant CCL5 had no enhancement in any of the experimental groups (Figure 4-16A). 
While it appears that CCL5 is not involved in monocyte induction of T cell proliferation, the 
caveat to our in vitro system is that it eliminates the chemokine gradient. A Transwell 
migration system with RANTES knock-out monocytes, adding in recombinant CCL5 would 
be an appropriate assay to determine any contribution of CCL5 to monocyte cross-
presentation/cross-priming.  
 Rather than handpicking possible soluble mediators, I developed another in vitro 
assay in which R848-treated monocyte supernatants were transferred into wells containing 
other ligands to assess if R848 does induce soluble factors that drive T cell proliferation. For 
this, Ly6C+ monocytes were enriched and co-cultured with AOVA apoptotic thymocytes and 
TLR ligands overnight. Supernatant from R848-treated monocytes were then transferred 
into half of the wells with other TLR ligands (R848 media vs control media). CFSE-labeled 
OT-1 T cells were then added to the wells, and the number of proliferative cells determined 
after 72 hours. In these experiments, R848 supernatant slightly enhanced the total number 
of proliferative CD8+ T cells of PBS, LPS and CpG treatment groups, although enhanced 
proliferation was not significant (Figure 4-16B). Interestingly, R848 slightly reduced 
proliferation in wells containing Pam3 and Sa19, also not significant. Collectively, it appears 




Figure 4.16 R848-mediated CD8+ T cell proliferation is not due to a secreted mediator 
produced by Ly6C+ monocytes. (A) CD45.2+ Ly6C+ monocytes were enriched and FACS sorted 
to obtain pure populations. They were then co-cultured with AOVA apoptotic thymocytes, enriched 
CFSE-labeled OT-1 T cells, TLR ligands with or without recombinant CCL5. After 72 hours, total T 
cell numbers were quantified. Experiment was performed twice, with three wells per group. (B) 
Enriched CD45.2+ Ly6C+ monocytes were enriched and cultured with TLR ligands for 18 hours. After, 
supernatant from R848-treated wells was transferred into half of the wells containing other TLR 
ligands. CFSE-labeled OT-1 T cells were then added, and after three days the number of OT-1 T cell 
was quantified by flow cytometry. Graph displays quantification of proliferative OT-1 T cell numbers 
from wells that did not receive the R848-supernatant (Control Media) and those that did (R848 















proliferation. However, there are caveats to the supernatant transfer experiment, in that the 
proximity of the soluble factor may act locally and the transferred portion may have not 
contained it, or also, there may need to be a constant supply/signal in which a bolus 
treatment was not sufficient. Additionally, the enhancement of T cell proliferation upon R848  
treatment was not as robust as previous experiments. This is likely a technical error, in 
which these experiments used enriched monocytes (to obtain higher yields), rather than 
sorted monocytes. The enrichment strategy for splenic monocytes is not highly efficient, and 
contaminating T and B cells in the enriched pool may be diluting out previously observed 
proliferative responses from sorted monocytes. Ultimately, while R848 promotes the 
activation and proliferation of CD8+ T cells in vitro, it remains inconclusive as to whether 
R848 promotes the release of a CD8+ T cell differentiation factor.  
Do R848 treated monocytes induce the differentiation of naïve CD8+ T cells to become 
cytotoxic effectors?  
 Next, I wanted to determine if Ly6C+ monocytes drive the differentiation of CTLs, 
particularly in the presence of R848. Batf3-/- mice were used for these studies so that in vivo 
responses could be assessed in the absence of CD8α+ DCs. The use of these mice were 
critical, as CD8α+ DCs are known to generate CTLs against cell-associated antigen154. OT-1 
T cells were intravenously injected into either WT or Batf3-/- mice (Figure 4-17A). The 
following day, mice were immunized intravenously with AOVA apoptotic thymocytes and 
either PBS, LPS or R848. Five days following antigen exposure, CFSE-labeled target cells 
that were either CD45.1+ (OVA-) or CD45.2+ (OVA+) were injected at a 1:1 ratio. The 
following day, spleens were harvested for FACS analysis, measuring the ratio of CD45.1 to 
CD45.2 target cells to assess antigen-specific killing. In PBS control treated mice (not 
receiving antigen), target cells remained at approximately a 1:1 ratio (Figure 4-17B, C). 
Mice receiving AOVA apoptotic cells without TLR ligand treatment had minor antigen-





Figure 4.17 R848-treated Ly6C+ monocytes do not efficiently cross-prime CTLs in 
vivo, partially attributed to the lack CD8+ T cell proliferation. (A) Experimental set up. OT-I 
T cells were transferred into WT and Batf3-/-mice 1 day prior to intravenous immunization with PBS or 
AOVA apoptotic thymocytes ± LPS or R848. 5 days later, mice were intravenously injected with (1:1) 
CFSE-labeled CD45.1+ (OVA-) and CD45.2+(OVA+) target cells. (B, C) 24hr post target cell transfer, 
cytotoxicity was assessed by flow cytometry. Dot plots display the frequencies of transferred target 
cells. Graph displays frequency of transferred target cells: OVA+ (closed) and OVA- (open). Data is 
cumulative of three independent experiments with 2-3 mice per group. (D) WT and Batf3-/- mice were 
intravenously injected with CFSE-labeled apoptotic thymocytes for one hour. After, spleens were 
harvested and the percentage of CFSE+ Ly6C+ monocytes were quantified. Graph represents two 
independent experiments with 1-2 mice per group. (E) WT mice were treated with AOVA apoptotic 
thymocytes and PBS, Pam3 or R848 for one hour. Spleens were then harvested and Ly6C+ 
monocytes were enriched and co-cultured with CFSE-labeled OT-1 T cells. After three days, the 
number of proliferative OT-1 T cells were quantified. Data are representative of one experiment, with 




were treated with LPS and R848, there was almost complete antigen-specific killing, likely 
induced by the Batf3+ DCs. To our surprise, in the Batf3-/- mice, LPS treatments still induced 
significant antigen-specific killing. R848 treatment in Batf3-/- mice did induce some antigen-
specific killing, but was not significant. This was not due to an impairment of Batf3-/ 
monocytes to engulf the antigen-expressing apoptotic thymocytes. Monocyte efferocytosis  
was measured in WT and Batf3-/- mice by intravenously treating mice with CFSE-labeled 
apoptotic thymocytes and either PBS, LPS or R848 for one hour. In both WT and Batf3-/- 
mice, R848 enhanced the proportion of CFSE+ Ly6C+ monocytes (Figure 4-17D). Lastly, I 
wanted to determine if R848 also enhances CD8+ T cell proliferation in vivo.  WT mice were 
intravenously treated with AOVA apoptotic thymocytes with either PBS, Pam3 or R848. After 
an hour, Ly6C+ monocytes were enriched and co-cultured with CFSE-labeled OT-1 T cells 
for 72 hours. In this experiment, Pam3, but not R848, enhanced the total number of 
proliferative T cells (Figure 4-17E). While more experiments need to be done to confirm, this 
suggests that R848 does not enhance CD8+ T cell proliferation in vivo as it does in vitro, and 
in fact, other TLR ligands may better at enhancing T cell proliferation in vivo. This could be 
an explanation as to why CTL responses in the presence of R848 was not significant.  
Does CD8+ T cell proliferation induced by R848-treated monocytes in vitro require 
TLR signaling? 
 It was previously observed that enhanced monocyte efferocytosis with ligand 
treatment is dependent on specific TLR ligation and signaling through the downstream 
adaptor molecule MyD88. Given this, I predicted that R848-mediated T cell proliferation 
would be attributed to signaling events that enhance the physical loading of peptide onto 
MHC Class I, the upregulation of co-stimulatory molecules, or the release of soluble 
mediators. However, with R848 treatment I didn’t see a selective enhancement of any of 
these processes. Therefore, I wanted to determine if R848 also signals through TLR7 to 
enhance in vitro T cell proliferative responses. First, I evaluated the necessity of TLR7 for 
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R848-enhanced T cell proliferation. WT and TLR7-/- splenic monocytes were enriched and 
FACS sorted, then co-cultured with AOVA apoptotic thymocytes, CFSE-labeled OT-1 T cells 
and either PBS or R848 for 72 hours. The number of proliferated T cells cultured with WT or 
TLR7-/- monocytes was enhanced with R848 treatment, and there was no significant 
difference comparing WT monocytes and TLR7-/- monocytes treated with R848 (Figure 4-
18A). I performed similar experiments using monocytes deficient in MyD88. I saw the same 
results, in that R848 enhanced T cell proliferation in monocytes both sufficient and deficient 
of signaling adaptor molecule (Figure 4-18B). Lastly, as R848 is a TLR7/8 ligand, I wanted 
to determine if TLR7-specific ligands – CL264 and Imiquimod (R837) – equivalently 
enhanced T cell proliferation as R848. WT monocytes were enriched and co-cultured with 
AOVA apoptotic thymocytes and CFSE-labeled OT-1 T cells with PBS, CL264, R837 or 
R848. After three days, only R848 enhanced the total number of proliferative T cells (Figure 
4-18C). Together, this suggests that R848 acts through an unknown receptor on monocytes 
to enhance T cell proliferation in vitro, independent of TLR7 or MyD88-dependent receptors. 
Discussion 
 Collectively, this chapter dissects Ly6C+ monocyte processes that are enhanced by 
TLR ligation (TABLE 4-1). I first show that engulfment of apoptotic cells is enhanced by TLR 
stimulation, and the degree of enhanced efferocytosis loosely correlates to transcript 
expression on naïve monocytes, where TLR2, TLR7 and TLR13 had the highest transcript 
per million count reads, and treatment with their agonists displayed the greatest proportion 
of monocytes that efferocytosed. Additionally, enhanced efferocytosis was dependent on 
receptor and MyD88 signaling. As efferocytosis was measured at just one hour, which is 
likely too short of time to induce transcription of potential scavenger receptors. TLR 
signaling likely induced post-translation signaling changes that aid in the uptake. Several 
examples of these modifications include actin cytoskeletal rearrangements and recruitment 




Figure 4-18 R848 does not require TLR7 or MyD88 for enhanced T cell proliferation in 
vitro. (A-C) CD45.2+ Ly6C+ monocytes were enriched and FACS sorted to obtain pure populations. 
They were then co-cultured with AOVA apoptotic thymocytes, CFSE-labeled OT-1 T cells and PBS or 
R848. After 72 hours, total T cell numbers were quantified. Experiments were performed in either (A) 
TLR7-/- or (B) MyD88-/- mice or (C) WT mice treating with the TLR7 ligands CL264 and R837. 








































phagocytic cup formation requires the phosphorylation of Rho guanine triphosphate 
(GTP)ases that can occur by TLR signaling. Furthermore, TLR transcript expression also 
loosely correlated to the upregulation of MHC Class I and the co-stimulatory molecules 
CD40 and CD80 on Ly6C+ monocytes after TLR ligation for 18 hours. However, blocking 
CD40 or CD80/86 interactions had no significant impairment on T cell proliferation. Despite 
the dogma for the requirement of co-stimulatory molecules on activating CD8+ T cells, there 
have been reports in which co-stimulation is not necessary147,196. However, these studies do 
not address T cell longevity, in which co-stimulation may minimize apoptosis without 
enhancing proliferation. Furthermore, T cell enrichment strategies may alter their need for 
co-stimulation, as the CD8 molecule was shown to be required for co-stimulatory molecule 
independent activation.  
In addition to increased co-stimulatory molecule expression, Pam3, R848 and Sa19 
also had a larger proportion of monocytes that retained their original size after the 18-hour 
culture. While monocyte cell shrinkage did not correlate with cell viability by DAPI stain, it 
remains possible that monocytes, particularly with LPS treatment, were beginning the 
process of apoptosis. To this point, HaCaT keratinocytes treated with a substantial dose (50 
µg/ml) of poly I:C for 24 hours showed that caspase-8 was not cleaved/activated until at 
least 16 hours of incubation197. Together this suggests that TLR-induced apoptosis is a 
delayed process, and that after an 18-hour incubation with TLR ligands Ly6C+ monocytes 
may not have a compromised membrane identifiable by DAPI staining.  
Interestingly, naïve Ly6C+ monocyte TLR transcript expression or localization within 
the endosome had no bearing on T cell proliferative responses in vitro. R848, the TLR7/8 
ligand, enhanced naïve CD8+ T cell activation, proliferation and IFN  production in vitro. 
While R848-mediated efferocytosis is TLR7-dependent, the signaling mechanism utilized for 
activating naïve CD8+ T cells remains elusive. It has been shown that R848 can signal 
through the NLRP3 inflammasome, whereas other TLR ligands including LPS and Pam3 
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does not198. Furthermore, preliminary data evaluating CD8+ T cell proliferation induced by ex 
vivo Ly6C+ monocytes showed that Pam3, likely signaling through TLR2, enhanced T cell 
proliferation, whereas R848 did not. Additional in vivo studies utilizing mice deficient in 
CD8α+ DCs are needed, for example the use of XCR1-DTR mice, in conjunction with other 
TLR7 agonists, to better evaluate the role of TLR7 signaling on Ly6C+ monocyte cross-
presentation and cross-priming. 
This alternative signaling pathway could explain the cytotoxic responses upon 
administration of LPS, but not R848; in that TLR(4) signaling can induce cross-priming of 
monocytes in vivo, while NLRP3 signaling does not. This hypothesis is supported by a study 
showing that NLRP3 was not required for the inflammasome mediated cross-priming against 
influenza virus199. 
In addition to the TLR ligands discussed, poly I:C, a TLR3 agonist was also included 
in early studies. However, like CpG, poly I:C treated monocytes did not enhance either 
efferocytosis or the induction of T cell proliferation. This could potentially be due to the 
transcript expression of TLR3, which was lower compared to other TLR ligands, or 
alternatively, monocytes may not utilize the Trif signaling adaptor molecule like DCs do. It 
would be interesting to determine if efferocytosis and the minor CTL responses observed by 
LPS was due to signaling through endosomal Trif or surface Myd88. Studies assessing 
efferocytosis upon LPS treatment in Myd88-/- suggested LPS utilizes Myd88 signaling 
pathways; however, this does not address either compensatory mechanisms by Trif 
signaling, or the signaling pathways utilized in the downstream induction of T cell activation.  
When comparing Ly6C+ monocytes to CD8α+ DCs, I was surprised to find that in our 
studies while monocytes enhanced efferocytosis in response to TLR ligation, DCs did not. 
From this, it would be interesting to determine if Ly6C+ monocytes can have multiple ‘eating’ 
sessions, in contrast to DCs which reduce endocytosis upon activation. Interestingly, 
monocyte efferocytosis upon TLR ligation was comparable to that of the CD8α+ DCs. To this 
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point, monocyte-induced CD8+ T cell proliferation upon R848 treatment was also 
comparable to unstimulated CD8α+ DC proliferation in our in vitro studies. However, unlike 
DCs, R848-mediated T cell proliferation by Ly6C+ monocytes in vitro was independent of 
TLR7 and MyD88, and furthermore, did not promote cross-priming and the generation of 
CTLs154. Evidence supporting the inability of R848-treated monocytes to induce significant 
CTLS compared to DCs is the observed lack of IL-27 production, required for productive T 
cell responses200. Together, my findings support literature in the field that show that antigen 
acquisition does not correlate to cross-presentation efficiency, and furthermore, TLR ligation 






































Project Rational and Outline 
This study corroborates recent findings identifying the Ly6C+ monocyte as a 
mononuclear phagocyte with its own immunologic effector function, beyond terminal 
differentiation into recruited macrophages or DCs. Recent evidence showed that monocytes 
can acquire and traffic soluble antigens to draining lymph nodes to present to CD8+ T 
cells34,36,201,202. At the onset of this thesis, the ability of monocytes to acquire and present 
cell-associated antigen had not been directly characterized. I therefore sought to determine 
whether primary splenic Ly6C+ monocytes can acquire apoptotic cells and furthermore 
present cell-associated antigens from the dying cells to induce the activation of CD8+ T cells. 
Cell-associated antigen is of interest as cells are constantly being turned over as a part of 
normal tissue homeostasis, in addition to pathogenic assault. Therefore, understanding 
cross-presentation of cell-associated antigens is important in the context of infection and 
tumor immunity. Furthermore, I was interested in comparing the efficacy of these processes 
in the context of TLR stimulation or in the naïve state.  
 In Chapter III I first identified that naïve splenic Ly6C+ monocytes can acquire pieces 
of apoptotic cells (efferocytose). In fact, within the spleen there were equivalent numbers of 
efferocytic Ly6C+ monocytes as CD8α+ DCs. Ly6C+ monocyte acquisition of apoptotic cells 
was not limited to the mechanism of target cell death, as UV-induced and Dexamethasone-
induced apoptotic cells were both engulfed. While both Ly6C+ monocytes and CD8α+ DCs 
efferocytosed equivalently, their scavenger receptor profile by transcript expression 
suggests that they utilize different mechanisms for uptake. Furthermore, we assessed 
antigen processing within monocytes by measuring endosome acidification. Monocytes had 
equivalent acidification as CD8α+ DCs, suggesting antigenic peptide maintenance for the 
presentation onto MHC Class I molecules.  
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Apoptotic thymocytes that constitutively express the model antigen ovalbumin 
(AOVA) was used as the source of cell-associated antigen in my experiments. After 
incubation of monocytes with AOVA, I saw a sub-population of Ly6C+ monocytes that 
expressed both higher levels of co-stimulatory molecules as well as peptide: MHC Class I 
complexes on their cell surface. Furthermore, Ly6C+ monocytes can cross-present apoptotic 
cell derived antigens to induce the activation and proliferation of CD8+ T cells, a function 
thought to be predominantly attributed to the CD8α+ DCs (Figure 5.1, top panels). 
 In Chapter IV we evaluated how activated Ly6C+ monocytes acquire and present 
cell-associated antigen by using synthetic PAMP analogs to target specific TLRs. We 
showed that direct TLR ligation on Ly6C+ monocytes enhance the proportion of cells that 
could engulf apoptotic cells, both in vitro and in vivo. This contrasted with CD8α+ DCs, in 
which the presence of TLR ligands did not influence their efferocytic capacity. This suggests 
that monocytes have inducible effector functions, which include the acquisition of exogenous 
antigens (Figure 5.1 middle panels).  
Additionally, we saw that Ly6C+ monocytes in response to multiple TLR ligands 
enhanced co-stimulatory molecule expression, and were capable of activating CD8+ T cells 
to produce IFN . To our surprise, specifically the TLR7/8 ligand - R848 - selectively 
enhanced the proliferation of CD8+ T cells in vitro, independent of TLR7 or MyD88 signaling 
on the monocyte. However, these results from R848-treated monocytes did not replicate in 
our ex vivo and in vivo models. Yet, other TLR ligands that did not enhance CD8+ T cell 
activation in vitro did enhance CD8+ T cell proliferation ex vivo and cross-priming in vivo 
(Figure 5.1 middle, bottom panels). This highlights two concepts: the importance of 
verifying if in vivo experiments parallel in vitro, findings and, also the requirement of TLR 




Figure 5.1 Ly6C+ monocyte acquisition, cross-presentation and cross-priming of cell-associated 
antigens. Unstimulated splenic Ly6C+ monocytes and CD8α+ DCs (grey circles) can acquire cell-
associated antigens (derived from apoptotic cells) and present to naïve CD8+ T cells (blue circles) to 
induce T cell proliferation (top panels). Upon TLR stimulation, efferocytosis is enhanced by monocytes, 
while DCs maintain their intrinsic ability. In contrast, cis-TLR ligation on DCs enhanced CTL responses, 
greater than monocytes (middle panels). TLR ligation independent of TLR signaling in vitro does not 
induce CTL responses in either DCs or monocytes. However, R848 specifically enhances monocyte 
induction of T cell proliferation in vitro. The mechanisms for R848 TLR-independent signaling remains 











In these studies, I show that monocytes are contributors to both innate and cytotoxic 
adaptive immune responses. However, as this is an emerging field there are many 
questions that are still unanswered. Specifically, can Ly6C+ monocytes be further subdivided 
to elude to their function(s) in regulating immunity? and how do monocytes contribute to 
physiologic adaptive immune responses (tumor, infection, graft rejection, central/peripheral 
tolerance)? As correlative monocyte populations have been identified in humans, 
addressing these questions are imperative, with high prospect translating mouse models to 
humans.  
Monocytes as Migratory Antigen Presenting Cells 
Conventional DCs are considered the primary cross-presenting cells of exogenous 
antigens. Yet, there is growing interest in the ability of other cell types to cross-present, 
including Ly6C+ monocytes. My interest in Ly6C+ monocyte cross-presentation arose for 
several reasons, largely due to observations that they are truly the migratory mononuclear 
phagocyte, compared to DCs or macrophages (Figure 5.2).  
In support of this, Ly6C+ monocytes are morphologically and phenotypically 
equipped for migration. Ly6C+ monocytes are just slightly larger than lymphocytes, which 
enables travel through most of the bloodstream, including capillary beds, with relative ease. 
In contrast, macrophages are larger in diameter and therefore not considered very motile. 
Additionally, Ly6C+ monocytes express a range of surface receptors and adhesion 
molecules that aid in emigration from the bone marrow and directive recruitment to tissues. 
CCR2 expressed on Ly6C+ monocytes is required for the egress from the bone marrow into 
the bloodstream203,204. CCR2 can bind both CCL2 and CCL7, which upon infection are 
detected in serum, tissues, as well as within HEVs. Promiscuous chemokine release 
promotes monocyte emigration from the bone marrow, as well as trafficking to the lymph 
nodes35,204,205. There is evidence that monocytes can acquire cell-associated antigens 




Figure 5.2 Differential migratory capacity of mononuclear phagocytes. Ly6C+ monocytes can be 
derived from bone marrow precursors, which either exit the circulation and enter tissues, or 
differentiate into Ly6Clo monocytes. Under some circumstances they can differentiate into recruited 
macrophages (MΦ). Ly6C+ monocytes can also traffic to LNs directly from the circulation via HEV, or 
from the tissue through afferent lymphatics. Monocytes can acquire antigen within the bone 
marrow/circulation or tissues to traffic to the LN. DCs arise from a precursor cell and seed tissues or 
lymph nodes directly where they can acquire antigen. Tissue DCs can also traffic to draining lymph 
nodes via afferent lymphatics.  









After egress from the bone marrow, Ly6C+ monocytes are largely unrestricted to the 
tissues they can enter, and upon inflammation robustly increase in cell number. This is 
partially due to the splenic reservoir that they can rapidly emigrate en masse207. Ly6C+ 
monocytes can enter both lymphoid tissues directly from the bloodstream, including lymph 
nodes via HEV or the spleen, as well as peripheral tissues, including the lung, skin, 
intestine, liver and even the brain34,203,206,208–214. As an example, Ly6C+ monocytes express 
the adhesion molecule L-selectin (CD62L) and CD44 that are required for monocyte 
trafficking into inflamed tissues and HEVs, as observed in the thioglycolate-induced 
peritoneum, and L. monocytogenes-infected liver215–218. Unique to Ly6C+ monocytes, once in 
tissues they can reenter circulation to traffic back to the bone marrow or traffic to lymph 
nodes by afferent lymphatics. This in in contrast to DCs, which reside in the tissues and are 
restricted to migration to the lymph nodes through afferent lymphatics. Thus, unlike tissue-
resident DCs and macrophages, monocytes are not restricted to tissue-specific antigens.  
In addition to monocytes’ trafficking ability, tissue monocytes are strategically located 
to promote the capture of antigen. For example, in the lung, they reside along the interface 
of capillaries and alveoli, in which they are capable of capturing particles from both the 
bloodstream and the airways219. Within the subcapsular red pulp a reservoir of monocytes 
can capture blood-borne antigens26. Increasing studies show upon antigen acquisition 
inflammatory monocytes traffic from peripheral tissues to subcapsular and paracortical T cell 
areas within the lymph node206,220. This implicates their role in cross-presenting exogenously 
acquired antigen to CD8+ T cells221,222. While it is clear DCs have a role in acquiring, 
trafficking and cross-presenting antigen, I posit that monocytes fill a niche in the antigens 
they can present, due to their access to the circulation and high migratory potential.  
Contribution of Monocyte Cross-Presentation In Vivo 
In these studies, monocytes have a clear ability to efferocytose,in both in vitro and in 
vivo settings, and their responsiveness to TLR ligands enhancing this process further 
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demonstrates that phagocytic properties of monocytes is a  key role in their contribution to 
immunity. However, in vitro monocyte cross-presentation and T cell activation were not 
replicated in vivo, particularly when monocytes were treated with the TLR7 ligand R848. In 
the in vitro experiments, activated monocytes are in close proximity to not only to the TLR 
ligands, but also to the naïve T cells at non-physiological numbers, and therefore the 
experimental system is biased to promoting monocyte cross-presentation of antigens to 
naïve T cells. In vivo, monocytes and T cells are spatially separated. While it has been 
described that monocytes can traffic antigens from non-lymphoid tissues to the T cell areas 
within this lymph node, it is unclear that within the spleen monocytes can traffic from the 
subcapsular sinus region or red pulp within the white pulp to activate naïve T cells. Future 
imaging experiments would be needed to identify the trafficking patterns of splenic 
monocytes once they have acquired apoptotic cells and determine if they do migrate into the 
T cell zone to either interact with either DCs, for potential antigen transfer, or with T cells, to 
directly activate naïve cells.  
Subpopulations of Ly6C+ Monocytes 
 In our studies, we identified a sub-population of Ly6C+ monocytes that expressed 
high levels of co-stimulation, and higher expression of surface peptide:MHC Class I 
complex. This made us question if within the murine Ly6C+ monocyte subset these cells 
could be further sub-divided with specific, non-redundant roles in regulating immunity? 
Additionally, if this is true, what drives Ly6C+ monocytes to differentiate into functionally 
different cells – a nature versus nurture phenomena?  
The generation of the chemokine reporter mouse CX3CR1 identified a clear 
CX3CR1+ (Ly6Clo) and a CX3CR1- (Ly6C+) population31,223. Ly6C+ monocytes have been 
shown to differentiate into Ly6Clo monocytes after emigration from the bone marrow, 
requiring the transcription factor Nur7728,32. In addition, within tissues Ly6C+ monocytes can 
differentiate into monocyte-derived DCs (mo-DCs), dependent on IRF4110. Together, this 
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suggests that monocyte differentiation is due to environmental cues that regulate 
transcriptional differentiation. In fact, monocyte-endothelial cell interactions by 
transmigration induces the upregulation of MHC Class II on a percentage of blood 
monocytes, further indicating the environment drives differentiation and consequently their 
roles in immunity. This transmigration also promoted monocyte antigen-presenting 
potential87. One would likely predict that the co-stimulatory positive sub-population of Ly6C+ 
monocytes have differentiated into mo-DCs. Interestingly, splenic Ly6C+ monocytes treated 
with both LPS and R848 had an increase in transcript expression of IRF4 and a reduction of 
Nur77, supporting the hypothesis that TLR stimulus promotes their differentiation into mo-
DCs. However, after Ly6C+ monocytes were cultured for 18 hours, I did not see CD11c 
surface protein upregulation, often associated but not required for mo-DC differentiation. 
Ultimately, monocyte differentiation into mo-DCs is an argument of semantics, as 
characterization can be dependent on timing, tissues and antigen type/burden34. We now 
know that monocytes observed to upregulate MHC Class II and traffic into tissues, 
suggesting the acquisition of DC-like characteristics, still maintain their monocyte 
transcription profile. Therefore, perhaps a more appropriate term to use is ‘activated 
monocytes’ rather than mo-DCs.  
We have evidence to assume that the co-stimulatory positive Ly6C+ monocyte 
population observed in these studies are equivalent to the CD43+, Ly6C+, MHC Class II+ 
observed in vivo by Jakubzick, et al34. In that study, MHC Class II+ monocytes had a 
selective advantage to induce CD8+ T cell proliferation, and therefore I would predict that the 
co-stimulatory positive, ‘activated’ monocytes in this study are also the cells responsible for 
inducing CD8+ T cell proliferation. First, we would need to determine if this sub-population is 
truly better suited to present antigen to CD8+ T cells by FACS sorting strategies. Also, 
determination of co-stimulatory positive Ly6C+ monocytes present in vivo across tissues 
would be needed. If there is truly a co-stimulatory positive subpopulation, I would predict 
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they would also preferentially traffic antigen to LNs, which raises another question – are the 
co-stimulatory positive monocytes better equipped to acquire antigen? Additionally, it would 
be interesting to perform single-cell RNA sequencing comparing in vivo and in vitro PBS or 
R848 treated monocytes to determine if R848 induces the same signaling cascade in vitro 
and in vivo. This could give insight into how R848 treated monocytes enhance CD8+ T cell 
proliferative responses in vitro. These studies would elaborate on Ly6C+ monocyte sub-
populations having distinguished roles in regulating immunity, and could begin to address 
the cues that drive their differentiation.  
Are Splenic Ly6C+ Monocytes Representative Tissue Monocytes?  
The spleen serves as a filter for blood, and therefore, blood-derived pathogens. It is 
the home for peripheral immune cells, including an array of phagocytes that trap and 
remove components within the circulation. Additionally, lymphocytes reside within the white 
pulp regions, in which the initiation of adaptive immune responses can begin. That, with the 
relative high numbers of monocytes made them candidate primary cells to use for my 
experiments.  
In addition to the bone marrow, the spleen can also support hematopoiesis224. The 
assumption is that BM- and splenic-derived monocytes are one of the same; however, there 
have been no formal studies addressing this. To this point, one study identified a cell type 
with distinct antigen-presenting capabilities derived from splenic HSCs that phenotypically 
resembled ‘tissue-resident’ monocytes - having CD11bhi, MHC Class IIlo, CD11clo 
expression225. In my studies, there is no knowledges if our monocytes were BM or splenic 
derived, or a combination of both. In attempts of understanding the role of monocytes in 
antigen presentation, the question of splenic monocytes having the same cross-presentation 
potential as other tissue resident monocytes is of interest, particularly as we are suggesting 
a sub-population of monocytes that is responsible for antigen presentation and potentially T 
cell priming.  
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Antigen Type Determines Cross-Presentation Efficiency 
The type of antigen presenting cell, its differentiation status and mechanisms utilized 
for antigen acquisition all contribute to cross-presentation efficiency. The regulation of 
adaptive immunity in the presence of cell-associated antigens remains controversial226. 
Likely, apoptotic cells provide both positive and negative signals. Broadly, the current view is 
that the acquisition of antigenic material from apoptotic cells by immature DCs induce 
tolerogenic stimulus for T cells, whereas mature DCs induce immunogenic T cell responses. 
Whether this is true for Ly6C+ monocytes has not been clearly addressed.  
Mechanisms of uptake influences cross-presentation efficiency 
It is suggested that the form of antigen i.e., soluble versus cell-associated (from 
apoptotic cells or necrotic cells) versus immune complexes, and therefore route of uptake 
and endosome processing, dictate cross-presentation efficiency112,227. Soluble antigen has 
been shown to be poorly presented compared to apoptotic or necrotic cells, possibly due to 
its lack of requirement for endosome acidification and cytosolic proteolysis228. Additionally, 
OVA protein linked to latex beads is presented onto MHC Class I molecules up to ten-fold 
more efficiently than soluble OVA alone229.  
Furthermore, antigen delivery route influences cross-presentation efficiency, and as 
such, opsonization and targeting antigens to surface receptors enhance antigen cross-
presentation230. Focusing on apoptotic cell acquisition, Batf3+ DCs utilize the scavenger 
receptor DC-SIGN, and targeting antigens directly to this receptor via anti-receptor 
antibodies that are covalently linked to the antigen enhanced cross-presentation 
efficiency231. This was further evidenced by targeting antigen binding to specifically the neck 
region, with resulted in prolonged localization within the early endosome and therefore 
delayed lysosomal degradation99. Additionally, Clec9a can recognize dying cells, but rather 
than aiding in uptake, has been shown to promote the co-localization of engulfed dying cells 
to early and recycling endosomes, in turn promoting CTL responses232.  
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In my studies, splenic Ly6C+ monocytes did not cross-present soluble OVA, yet, they 
acquired soluble antigen robustly (data not shown). One could hypothesize that the 
mechanisms of apoptotic cell uptake, possibly through CD68 or Scara1, traffic antigen to the 
early endosomes, whereas soluble antigens are quickly shuttled to lysosomes, promoting 
the degradation of the SIINFEKL epitope. Additionally, RNA transcript data shows that 
monocytes do express low levels of DC-SIGN, which could be an alternative scavenger 
receptor to investigate for future studies. Ultimately, this has clinical implications in vaccine 
design strategies, in that the specific targeting of antigens may prove more efficient at 
promoting cross-presentation in monocytes that are more robust at infiltrating lymph nodes 
and may therefore induce more robust T cell responses.  
Cross-presentation of cell-associated antigens  
It is generally accepted that apoptotic cells are removed ‘quietly,’ while necrotic are 
potent inducers of inflammation by the release of intracellular contents, or danger-
associated molecule patterns (DAMPs) that can bind PRRs, including TLRs. Yet, there is not 
strong evidence that necrotic cells are more potent at inducing CTL responses. In fact, 
apoptotic and secondarily apoptotic cells acquired by DCs were shown to activate T cells, 
but freeze-thawed or hypotonic shock-induced necrotic cells did not233–235. This suggests 
that the mode of cell death, and likely plasma membrane organization is relevant in the 
presentation of dying cells. Biologically, necrotic cells are rarely seen, except when there are 
defects in the clearance of apoptotic cells, as implicated in systemic lupus erythematosus 
(SLE). Therefore, it can be reasoned that CTL responses against necrotic cell-derived 
antigens would not be beneficial.   
Further differences in efficiencies to cross-present cell-associated antigens could be 
derived from exposure dose. One study showed that, cross-presentation efficiency of 
apoptotic cells was better than necrotic at low doses, but this was abrogated at higher 
concentrations of each dying cell type228. Furthermore, in vivo models of tumor challenge 
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showed that only injecting large numbers of tumor-antigen expressing apoptotic cells induce 
antigen-specific CTL responses236. However, this also correlated to increased serum 
concentration of IL-10, shown to negatively impact tumor cell rejection (discussed more 
below).  
In my studies, preliminary experiments support this dose effect of apoptotic cells. I 
found that an increased ratio of apoptotic cells to Ly6C+ monocytes minimized the enhanced 
effect of R848 treatment inducing CD8+ T cell proliferation in vitro. While I would assume 
that monocytes, as DCs, do not efficiently cross-present antigen associated with necrotic 
cells, I have not formally tested this. In the in vitro T cell proliferation assays, apoptotic cells 
may have become necrotic, altering my interpretation of monocyte induced CD8+ T cell 
proliferation. This may be an explanation as to why in vitro proliferative responses by R848 
treated monocytes were not replicated ex vivo.   
Interactions of apoptotic cells with myeloid phagocytes 
Differences in cell type may also dictate pro- versus anti- inflammatory responses in 
the presence apoptotic cells. Monocytes may contribute to immunosuppression, as they 
have been shown to secrete IL-10 in the presence of apoptotic cells and reduce pro-
inflammatory cytokine production, such as IL-1284. However, in DCs, apoptotic cells were 
shown to induce dose-dependent production of both inflammatory (Il-1 , TNFα) and anti-
inflammatory (IL-10, TGF- ) cytokines, as well as upregulate co-stimulatory molecules234,237. 
It would be informative to determine how each efferocytic cell type coordinates various input 
signals in the presence of apoptotic cells to mediate diverse immune responses.  
Furthermore, it would be interesting to determine if monocyte sub-populations (MHC Class 
Ihigh vs MHC Class Ilo) have differential cytokine (IL-10) production.  
Ly6C+ Monocytes as Suppressor Cells 
This study corroborates emerging evidence that monocytes have their own effector 
functions and the acquisition of apoptotic cell derived antigens implicates their involvement 
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in tumor biology. However, generation of CTL responses against self-antigens from dying 
cells is not always beneficial to the host. One could hypothesize that antigen-acquiring 
monocytes counter-balance potentially harmful cytotoxic immune responses from dying cells 
through suppressive – either direct or indirect – mechanisms.  
Monocytic myeloid-derived suppressor cells (mMDSCs) 
 The most common example of monocytes exhibiting suppressor responses is in the 
context of cancer biology; however, myeloid-derived suppressor cells (MDSCs) also shape 
the immune system during infection, sepsis or transplantation238. mMDSCs are broadly 
characterized as myeloid-originating CD11b+Ly6C+ cells with the ability to suppress T cell 
responses. Growth factors, cytokines and chemokines such as GM-CSF, CCL2, IL-1 , IL-6, 
IL-8 and IL-10 promote the recruitment and activation of MDSCs, as well as TLR ligation 
and MyD88 signaling239. mMDSCs dampen T cell proliferative responses by iNOS activity 
and local ROS production240. In addition, suppression can occur by the production of IL-10 
or the upregulation of PD-L1241.  
TLR ligation and signaling activating mMDSCs could be an explanation for R848 
enhancement of T cell proliferation in vitro. If TLR signaling promotes mMDSC development 
and R848 does not signal through TLR7 or MyD88 on Ly6C+ monocytes, then R848 may be 
inducing activated monocytes whereas the other TLR ligands inducing mMDSCs. However, 
if TLR signaling did induce monocyte suppressive activities, I would have expected non-TLR 
treated monocytes to promote stronger T cell proliferative responses, not equivalent, to TLR 
treated monocytes. Furthermore, characteristic to mMDSCs is the expression of iNOS or 
production of IL-10. Transcript expression from our Ly6C+ monocytes, with either LPS or 
R848 exposure, had minimal expression of both.  
Monocyte suppression through competition  
Ly6C+ monocytes are equivalently capable of acquiring antigen as CD8α+ DCs, and 
upon inflammation outnumber DCs. Therefore, monocytes may indirectly act as suppressor 
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cells by simply diluting the amount of antigen seen and therefore acquired by DCs. This is 
more relevant in endogenous settings, where antigen specific T cell precursor frequency is 
only about 100 cells242. 
Ly6C+ monocytes may also indirectly suppress DC responses as an artifact of less 
efficient peptide generation. The dominant epitope for OVA protein is SIINFEKL, but APCs 
can also present subdominant peptides243. The efficiency of peptide production for cross-
presentation are largely driven by the incorporation of inducible immunoproteasome 
subunits, LMP2, LMP7 and MECL1100. In our model, monocytes were capable of inducing T 
cell proliferation and CTL responses, but were not as efficient as CD8α+ DCs. While 
speculative, it is possible that monocytes utilize a different combination of inducible 
immunoproteasome subunits compared to DCs, and therefore, presenting suboptimal 
peptides to high affinity OT-1s. This argues against an active suppressive response, but 
rather, limited ‘inflammatory’ potential. Furthermore, in these studies R848 treatment of 
monocytes enhances transcript expression of LMP2 and Mecl1 compared to LPS treatment, 
which could explain the productive CD8+ T cell proliferative responses in vitro.  
Ly6C+ Monocyte Contribution in Promoting Cellular Immunity 
 When comparing the Ly6C+ monocyte and CD8α+ DC potential to initiate CD8+ T cell 
responses, on a per cell basis, DCs were more efficient at inducing both in vitro proliferation, 
as well as in vivo CTLs. Yet, studies show that upon infection, monocytes robustly traffic to 
draining lymph nodes and acquire antigens, both more robustly than DCs202.  This made us 
question how monocytes contribute to adaptive immune responses. Critical components that 
must be taken into consideration when assessing a particular cell types’ contribution to 
adaptive immunity include location, timing, and the nature of antigen. Several hypotheses 
could be that 1) monocytes assist DCs in driving effector T cell differentiation, 2) monocytes 
preferentially promote the differentiation of naïve cells into memory cells, rather than 
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effectors or 3) monocytes preferentially promote memory, rather than naïve, T cell 
activation.   
Ly6C+ monocytes may transfer antigen to DCs 
In these studies, I showed that splenic Ly6C+ monocytes do not rapidly acidify their 
endosomes, in contrast to macrophages. This suggests they retain some antigenic peptides, 
presumably to cross-present to CD8+ T cells. While Ly6C+ monocytes can directly induce T 
cell proliferation, it is not as robust as the CD8α+ DCs. Therefore, it is possible Ly6C+ 
monocytes primarily acquire and retain antigen to transfer to DCs for more efficient cross-
priming.  
The concept of antigen transfer has been shown in multiple settings, for example, 
dermal DCs can transport viral antigens to LN-resident CD8α+ DCs which then generate 
CTLs244. Additionally, inflammatory monocytes were shown to robustly acquire labeled 
antigen (yeast, influenza-infected apoptotic cells) and traffic to the draining lymph node, but 
did not present peptide fragments on their surface or induce T cell proliferation222,245,246. 
However, upon blocking this migration, CTL responses were attenuated, further implicating 
the role of monocytes in trafficking and transferring antigens.  
Monocytes transferring antigen further supports their roles in immunity by promoting 
visualization of tissue-restricted antigens. To this point, CD11b+ DCs are not effective at 
acquiring antigens from dying cells, and therefore are restricted to the CTLs they can 
induce. Monocytes could exploit this by directly engulfing dying cells and transferring 
antigen to DCs that would not otherwise come into contact, or be capable of, acquiring a 
given source of antigen.  
Ly6C+ monocytes may aid DC cross-priming 
In a recent report, naïve CD8+ T cells were shown to require sequential stimulus to 
undergo differentiation into their cytotoxic forms247. Primary stimulus occurs by a rapid wave 
of IL-12 production by white-pulp resident DCs248. Upon T cell activation and proliferation, 
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they migrate out of the white pulp into the marginal zone of the red pulp via bridging 
channels, in which proliferation continues249. Within the marginal zone, CD8+ T cells can 
cluster around myeloid cells, that produce a secondary wave of IL-12. Secondary IL-12 
stimulus leads to prolonged CD25 expression, and the generation of short-lived effector 
cells250,251. The likely candidate for the secondary IL-12 are CD11b+ DCs that reside in the 
marginal zone252. However, restrictions in antigen acquisition (soluble versus cell-
associated) or exposure could suggest a niche for monocytes within the spleen to provide a 
secondary (or tertiary) cytokine signal to aid in T cell differentiation as the T cells emigrate 
from the spleen to the bloodstream. Ly6C+ monocytes increase in IL-12 transcript upon TLR 
ligation (LPS and R848); however, more conclusive studies would need to be performed in 
determining if monocytes do secrete cytokines that aid in the differentiation or maintenance 
of effector T cells. Furthermore, co-culture experiments with Ly6C+ monocytes and/or 
CD11b+ DCs with CD8α+ DCs measuring T cell effector differentiation would elude to 
monocyte contribution to DC cross-priming.  
Monocytes may promote differentiation of naïve T cells into memory rather than 
effector cells  
The optimal differentiation of T cells into CTLs is dependent on IL-12253. In the 
absence of IL-12 CD8+ T cells are still able to proliferate, but differentiate into memory cells 
rather than short lived effector cells. Though splenic Ly6C+ monocytes increased IL-12 
transcript upon TLR ligation, our studies did not show evidence of protein production. This 
suggests that the Ly6C+ monocytes in these experiments may promote the differentiation of 
naïve CD8+ T cells into memory, rather than effector cells.  
Alternatively, it has been shown memory formation can be triggered by CD27/OX40 
ligation on the CD8+ T cells, serving as an alternative signal 3 rather than IL-12254. Naïve 
splenic monocytes did not express transcript for CD70 or OX40L, and LPS and R848 
treatment did not promote transcription, suggesting if monocytes do induce memory, this is 
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through an alternative mechanism. Unfortunately, preliminary experiments assessing the 
induction of memory versus effector differentiation by monocytes using the surface markers 
KLRG1 and IL-7Rα were largely inconclusive (data not shown).  
Monocytes may promote CTLs upon secondary challenge 
Alternatively, rather than monocytes driving naïve T cell differentiation, it is possible 
monocytes are more involved in presenting antigen to memory T cells upon secondary 
challenge. First, monocytes have a short half-life that is likely not conducive for naïve T cell 
activation, as naïve CD8+ T cells typically remain in contact with DCs for 20 hours176. 
Though it could be possible that either T cell engagement or the acquisition of apoptotic 
cells prolongs the survival of antigen-presenting Ly6C+ monocytes. To support monocyte 
contribution to memory T cell activation, one of the cytokines Ly6C+ monocytes secrete is 
CCL5, a known chemokine for memory T cells that promotes sustained T cell responses255. 
Further, if monocytes do migrate through the splenic marginal zone or LN subcapsular 
region, they would be brought into prompt contact with memory CD8+ T cells that migrate 
form the T cell zone upon inflammation within hours. A possibility is that monocytes are 
particularly well suited to help patrol the peripheral tissues and increase the chances that 
infected or insulted stromal cells are noticed quickly by an immune system tasked with 
monitoring tissues that vastly outnumber itself in number and volume. Monocytes may help 
in this by their increased motility and potentially help activate resident-memory CD8+ T cells 
within tissues.  
Monocytes Mimic Immature DCs 
 Immature DCs in the absence of pathogenic or inflammatory events are 
characterized by having high endocytic capacity and low expression of MHC Class II. In the 
absence of microbial stimulus, they do not upregulate proper co-stimulation, leading to 
impaired T cell activation. An appealing hypothesis is that monocytes resemble immature 
DCs in their ability to present antigen, particularly as blocking the co-stimulatory molecules 
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CD80/86 and CD40 had minimal impairment on T cell proliferation. A study assessing 
proliferation induced by immature DCs had a similar CFSE dilution profile to that of the 
Ly6C+ monocytes in my studies, in that that were few rounds of proliferation (indicating TCR 
engagement), but there was an abundance of undivided T cells256. Furthermore, in these 
studies, immature DCs did not downregulate CD62L on the proliferating T cells. This directly 
paralleled a study measuring CD62L on proliferating T cells induced by LPS-activated 
monocytes36. However, while immature DCs did not promote effector T cells, upon 
secondary immunization there was no impairment in secondary responses. Therefore, the 
activated T cells induced by immature DCs were differentiated into functional memory, 
rather than becoming tolerized or anergic. Together, these suggest that TLR stimulus does 
not activate monocytes the same way as DCs, and that activated monocytes more closely 
resemble immature DCs rather than mo-DCs.  It would be interesting to follow up on our 
studies to determine the contribution of antigen-experienced T cells by monocyte activation 
upon secondary challenge.  
Concluding Remarks 
Monocytes are emerging as cells contributing to both innate and adaptive immune 
responses. Recent reports show that tissue-resident Ly6C+ monocytes can cross-present 
soluble antigens to induce CD8+ T cell proliferation. At the onset of this thesis, the ability of 
monocytes to cross-present antigen associated with dying cells, such as tumor antigens, 
and to cross-prime cytotoxic CD8+ T cell responses was undescribed. The interest in cross-
presentation, particularly with cell-associated antigen, derives from evolutionary purposes – 
as a ‘fallback’ mechanism for viral infections that do not replicate within APCs, as a tumor 
surveillance mechanism, and as a means to induce peripheral tolerance to self-antigens that 
are not synthesized within APCs. Additionally, there is emerging evidence of pathogens 
regulating DC function, particularly in enabling cross-presentation and cross-priming. 
However, there has not been exhaustive studies on how TLR signaling influence monocyte 
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effector function – in both acquiring and presenting antigens. As our knowledge expands in 
understanding the division of labor among mononuclear phagocytes - the bridges of innate 
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